non-coding RNAs in neuropathic pain

Theodora Kalpachidou, Kai K. Kummer, Michaela Kress
Institute of Physiology, Medical University of Innsbruck, Innsbruck, Austria.

Corresponding author:
Univ.-Prof. Dr. med. Michaela Kress
Institute of Physiology
Medical University of Innsbruck
Schöpfstraße 41
6020 Innsbruck
Austria (Europe)
Phone: +43-512-9003-70800 (-01,-02 secr. office)
Fax: +43-512-9003-73800
e-mail: michaela.kress@i-med.ac.at

Abstract

Neuro-immune alterations in the peripheral and central nervous system play a role in the pathophysiology of chronic pain in general, and members of the non-coding RNA (ncRNA) family, specifically the short, 22 nucleotide microRNAs (miRNA) and the long non-coding RNAs (lncRNA) act as master switches orchestrating both immune as well as neuronal processes. Several chronic disorders reveal unique ncRNA expression signatures, which recently generated big hopes for new perspectives for the development of diagnostic applications. IncRNAs may offer perspectives as candidates indicative of neuropathic pain in liquid biopsies. Numerous studies have provided novel mechanistic insight into the role of miRNAs in the molecular sequelae involved in the pathogenesis of neuropathic pain along the entire pain pathway. Specific processes within neurons, immune cells, glia as the cellular components of the neuropathic pain triad and the communication paths between them are controlled by specific miRNAs in immune cells, neurons or glia. Therefore, nucleotide sequences mimicking or antagonizing miRNA actions can provide novel therapeutic strategies for pain treatment, provided their human homologues serve the same or similar functions. Increasing evidence also sheds light on the function of IncRNAs, which converge so far mainly on purinergic signaling pathways both in neurons and glia, and possibly even other ncRNA species that have not been explored so far.
**Introduction**

Human neuropathic pain disorders are difficult to diagnose and treat due to their diversity, which even increases with the development of chronic pain. The most frequent neuropathic pain disorder is diabetic painful neuropathy (DPN), which occurs as a common complication of diabetes mellitus [2, 3]. Although good control of blood glucose levels can reduce the incidence of DNP mainly in type I diabetes, more than half of the patients still develop DNP for which only symptomatic therapy of low to moderate efficacy is available to date [4]. Neuroinflammatory signatures have been identified as critical components of DNP but its complex pathogenesis is still incompletely understood [4, 5]. Pathological neuro-immune communication has, likewise, been associated with other painful neuropathy such as neuropathic pain occurring in up to 50% of patients experiencing traumatic nerve injury as a consequence of accidents, warfare or surgical procedures [6-8]. Also the neurogenic complex regional pain syndrome (CRPS), an enigmatic complication of bone fracture or tissue injury, is associated with neuro-inflammatory deficits [9]. In the majority of patients symptoms largely resolve, however in 30% of cases the pain persists or even intensifies [10]. The beneficial effect of glucocorticosteroids in acute CRPS points towards pathophysiological mechanisms associated with neuro-immune dysfunction [10-12].

Such neuro-immune alterations in the peripheral and central nervous system play a role in the pathophysiology of chronic pain in general, and members of the non-coding RNA (ncRNA) family, specifically the short, 22 nucleotide microRNAs (miRNA) as regulators of gene expression act as master switches orchestrating both immune as well as neuronal processes. The long non-coding RNAs (lncRNA) can regulate gene expression but when containing multiple miRNA binding elements can serve as endogenous sponges neutralising these miRNAs. Several chronic disorders reveal unique miRNA and lncRNA expression signatures, which recently generated big hopes for new perspectives for the development of diagnostic applications. ncRNAs modulating both neuronal and immune processes further promise therapeutic potential for diseases with a neuro-immune component [13, 14]. Specifically, ncRNAs may regulate neuro-immune communication signals in the pain pathway by controlling macromolecular complexes in neurons, glia and immune cells. Understanding the concerted function of miRNA and lncRNAs in the regulation of nociceptive transduction and action potential generation, the synaptic transmission in the spinal dorsal horn and brain, the intercellular communication between neurons and non-neuronal cells, such as microglia, and the endogenous inhibitory control circuits, and defining their importance in the brain circuitries connected to cognitive, emotional and behavioural components involved in pain will shed new light on the so far enigmatic pathophysiology of neuropathic pain disorders. This review will focus on miRNAs and lncRNAs, as a large amount of literature suggests important and partially opposing roles for these ncRNAs in the establishment and chronification of neuropathic pain.

**microRNA**

**Generation of miRNA**

Pain conditions have been associated with deregulated miRNA expression from primary afferent nociceptors to brain areas associated with emotional components of pain perception [15-20]. Unique signatures of ncRNAs are associated with altered innate immune signalling and secreted miRNAs are even considered a new form of neuro-immune communication and control immune cell activity as well as neuron function [14, 21-23]. Thus, ncRNAs may act as essential modulators of processes for the establishment and maintenance of neuropathic pain.

Generation of mature miRNAs takes place within two distinct cellular compartments (Figure 1): In the nucleus, miRNAs are transcribed from DNA sequences by polymerase II as pri-miRNAs, processed by the RNAse-III enzyme Drosha and its auxiliary protein DGCR8 (Pasha) into 5’ capped and poly-adenylated pre-miRNAs, which can be several kilobases long, and may comprise one (monocistronic) or several (polycistronic) miRNA precursors [26]. Pre-miRNA sequences form characteristic hairpin loop structures of
~70 nucleotides with a two-nucleotide overhang at the 3’ end and 3’ hydroxyl and 5’ phosphate groups [26-28]. Alternatively, short introns forming a hairpin like structure called mirtrons can be spliced in a Drosophila-independent manner to be further processed into a pre-miRNA [29]. These recently discovered features illustrate unexpected flexibility and highlight how alternative RNA processing can encode multiple functions by individual transcripts. Pre-miRNAs are shuttled from the nucleus into the cytosol by Exportin-5 transporter molecules where the RNase-III enzyme Dicer cleaves them towards biologically active mature duplex single stranded miRNAs (~18-25 nucleotides) [26]. Both single stranded miRNAs derived from the 5’ arm (~5p) and 3’ arm (~3p) of the precursor can become integrated with Argonaute (Ago) proteins to form the RNA-Induced Silencing Complex (RISC, see Figure 1; [30]). Depending on the degree of homology, the miRNA induces translational repression (incomplete match) or target mRNA degradation (full match, not in mammals) is induced. More than 50% of mammalian miRNAs are located within host genes [31]. Especially those intragenic miRNAs exhibiting a high degree of conservation between species appear to be coordinately regulated and expressed with their host genes, either with synergistic or antagonistic correlation patterns [32, 33]. For example, a number of interleukin 6 (IL-6) regulated miRNAs are upregulated in rodent models of neuropathic pain and distinct functions have been described [34]. In contrast to intragenic miRNAs, the regulatory elements for extragenic miRNA are still largely enigmatic.

Potential prospect of miRNA patterns emerging as possible signatures for pain disorders.

miRNA in body fluids. In addition to their intracellular location and function, miRNAs are detectable in extracellular vesicles, such as exosomes, which are released e.g., by glia cells to cargo messages to other cell types in the central nervous system. Therefore, exosomes are anticipated to represent a specific mode of intercellular communication (for review see [35, 36]). In addition, they are detectable in body fluids, such as cerebrospinal fluid (CSF), blood plasma or saliva, where they can be exploited for diagnostic purposes as so called “liquid biopsies”. Extracellular miRNAs are emerging as important communication units not only for mental disorders but also in the pain pathway offering the advantage of long distance messaging [37, 38]. Several studies propose individual miRNAs or miRNA signatures for pathological pain disorders, such as CRPS, diabetic neuropathic pain or fibromyalgia. However, the assays available for these first studies assessing miRNAs in human body fluids cover only a small number of miRNAs and the marginal overlap for the same disease when assessed at different locations dampens the great hopes in the possible value of liquid biopsies for clinical use in pain diagnostics (see table 1).

Table 1: Deregulated miRNAs identified in liquid biopsies of patients with pain disorders.

| Disease                        | Detection method | Sample type                | # upregulated | # down regulated | miRNA deregulated in min. 2 studies on disease | Reference |
|--------------------------------|------------------|----------------------------|---------------|------------------|-----------------------------------------------|-----------|
| CRPS                           | qPCR array       | blood                      | 4             | 14               | RNU48; miR-15a; miR-21; mir-25; miR-29c;  miR-34a; mir-126; miR-212; mir-320B; miR-337; miR-367; miR-576; miR-645; mir-939; miR-1276; miR-1303 | [39]      |
| CRPS                           | qPCR array       | serum derived exosomes     | 62            | 70               |                                               | [40]      |
| CRPS responders vs non-responders | qPCR array     | blood                      | 1             | 32               |                                               | [41]      |
| CRPS responders vs non-responders | qPCR array     | serum derived exosomes     | 1             | 8                |                                               | [42]      |
In total, about 6’000-7’000 microRNA sequences have been identified, more than 2’000 in humans [47]. In order to retrieve all known and possibly currently unknown human miRNAs together with other ncRNAs and mRNAs, RNA sequencing (RNASeq) technologies represent the state of the art methodology for unbiased assessment of differentially expressed miRNA in patient and control cohorts [48, 49]. For miRNA quantification in tissue, different experimental settings and also tissues, such as dorsal root ganglia (DRG), spinal cord or brain, require the use of appropriate reference genes and reliability is significantly higher if three different reference genes are used [50]. However, due to profound technical improvements, only unbiased RNASeq provides sufficient reliability and specificity for the discovery of disease specific miRNA patterns.

Nonetheless, for blood components, as well as nerve biopsies, a number of differentially regulated miRNAs has been identified and their target genes validated with a possible prospect to better understand disease pathophysiology (Table 2). Two upregulated miRNAs (miR-124 and miR-155) target the histone deacetylase SIRT1, a structurally important promoter of axonal elongation, neurite outgrowth, and dendritic branching. SIRT1 also plays a role in memory formation by modulating synaptic plasticity and it has protective roles in several neurodegenerative diseases [51]. The downregulation of SIRT1 by miRNAs could thus be causally involved in neuropathic pain generation or in the exacerbation of the immune response [52]. Likewise, the increased IL-6 and VEGF expression resulting from decreased activity of miR-338-5p and miR-939, as well as miR-34a and miR-101 targeting Corticotropin releasing hormone receptor 1 (CRHR1) and Karyopherin beta 1 (KPNB1) are relevant candidates for the inflammatory component of neuropathic pain disorders [42, 53, 54].

Table 2: Deregulated miRNA in human samples including validated target genes

| miRNA       | Regulation | Target Gene | Gene description | Validation | Pain disorder | Tissue | Reference |
|-------------|------------|-------------|------------------|------------|---------------|--------|-----------|
| miR-124a    | ↑          | SIRT1       | Sirtuin 1        | LucA       | neuropathic pain patients | CD4+ T cells | [52]     |
| miR-132-3p  | ↑          | GRIA1       | Glutamate ionotropic receptor AMPA type subunit 1 | LucA       | neuropathic pain patients | WBC / sural nerve | [55]     |
| miR-155     | ↑          | SIRT1       | Sirtuin 1        | LucA       | neuropathic pain patients | CD4+ T cells | [52]     |
| miR-199a-3p | ↑          | SERPIN E2   | Serpin family E member 2 | LucA       | diabetes type II | plasma | [56]     |
miR-455-3p ↑ TUBB3 Tubulin beta 3 class III mimic + HIV included polyneuropathy plasma [57]

miR-34a ↓ XIST; YY1 X inactive specific transcript; YY1 transcription factor LucA CRPS blood [58]

miR-34a ↓ CRHR1 Corticotropin releasing hormone receptor 1 LucA CRPS blood [54]

miR-101 ↓ KPNB1 Karyopherin subunit beta 1 LucA neuropathic pain patients plasma / sural nerve [59]

miR-338-5p ↓ IL6 Interleukin 6 LucA CRPS plasma [42]

miR-939 ↓ VEGFA Vascular endothelial growth factor A LucA CRPS plasma [53]

miRNA tissue expression in rodent models
Similar to human studies, differentially expressed miRNAs are extensively explored in preclinical neuropathic pain models [34, 60-65]. In several of the routinely used models, specific miRNAs are up- or downregulated all along the pain pathway and described in a number of recent publications and reviews [60, 61, 63, 65-72]. The following section takes a more mechanistic approach and provides an overview of miRNAs dysregulated in tissues in relevant preclinical pain models for which a relevant target gene and insight into neuropathic pain mechanisms have been validated (see Table 3).

Table 3: Look-up table of deregulated miRNA and target genes related to neuropathic human pain disorders or preclinical models of neuropathic pain. For ethical reasons, bilateral CCI was excluded as a model.

| miRNA     | Regulation | Target                                      | Gene description                                                                 | Validation               | Pain model                          | Tissue      | Species | Reference |
|-----------|------------|---------------------------------------------|---------------------------------------------------------------------------------|--------------------------|-------------------------------------|-------------|---------|-----------|
| miR-15b   | ↑          | Bace1                                       | Beta-secretase 1                                                                | LucA                     | oxaliplatin-induced peripheral neuropathy DRG rat | [73]        |
| miR-18a   | ↑          | Kcna1; Kcnd3                                | Potassium voltage-gated channel subfamily A member 1; Potassium voltage-gated channel subfamily D member 3 | LucA                     | SNL DRG rat                         | rat         | [74]    |
| miR-19a   | ↑          | Kcna4; Kcn4; Kcnq5; Scn1b                   | Potassium voltage-gated channel subfamily A member 4; Potassium voltage-gated channel subfamily C member 4; Potassium voltage-gated channel subfamily Q member 5; Sodium voltage-gated channel beta subunit 1 | LucA                     | SNL DRG rat                         | rat         | [74]    |
| miR-19b   | ↑          | Kcna4; Kcn4; Kcnq5; Scn1b                   | Potassium voltage-gated channel subfamily A member 4; Potassium voltage-gated channel subfamily C member 4; Potassium voltage-gated channel subfamily Q member 5; Sodium voltage-gated channel beta subunit 1 | LucA                     | SNL DRG rat                         | rat         | [75]    |
| miR-32-5p | ↑          | Dusp5                                       | Dual specificity phosphatase 5                                                 | LucA                     | SNL spinal cord / rat               |             | [76]    |
| miRNA   | Target Gene(s) | Gene Product/Description                                      | Luciferase | Tissue/Condition/Species | miRNA Target Gene(s) | Gene Product/Description                                      | Luciferase | Tissue/Condition/Species |
|---------|----------------|---------------------------------------------------------------|------------|--------------------------|----------------------|---------------------------------------------------------------|------------|--------------------------|
| miR-92a | Kcnc4; Dpp10    | Potassium voltage-gated channel subfamily C member 4; Dipeptidyl peptidase like 10 | LucA       | SNL; DRG; rat            | miR-124a             | Sirtuin 1                                                     | LucA       | neuropathic pain patients | human; CD4+ T cells |
|         |                |                                                               |            |                          | Sirtuin 1            | Neuropathic pain patients                                    |            | WBC / sural nerve         | human               |
| miR-155 | Socs1          | Suppressor of cytokine signaling 1                            | LucA       | CCI; spinal cord / microglia; rat | miR-155              | Sirtuin 1                                                     | LucA       | neuropathic pain patients | human |
| miR-195 | Ptc1           | Patched 1                                                     | LucA       | infraorbital nerve CCI; brain stem; rap | miR-195              | Sirtuin 1                                                     | LucA       | spinal cord / microglia  | rat |
| miR-218 | Socs3          | Suppressor of cytokine signaling 3                            | LucA       | CCI; spinal cord / microglia; rat | miR-218              | Sirtuin 1                                                     | LucA       | CCI; spinal cord / microglia; rat |
| miR-221 | Socs1          | Suppressor of cytokine signaling 1                            | LucA       | CCI; spinal cord / microglia; rat | miR-221              | Sirtuin 1                                                     | LucA       | CCI; spinal cord / microglia; rat |
| miR-449a| Pparg          | Peroxisome proliferator-activated receptor gamma              | LucA       | SCI; spinal cord; rat     | miR-449a             | Sirtuin 1                                                     | LucA       | SCI; spinal cord; rat     |
| miR-455-3p| TUBB3         | Tubulin beta 3 class III                                      | LucA       | Paclitaxel-induced; spinal dorsal; rat | miR-500              | Glutamate decarboxylase 1                                     | LucA       | Paclitaxel-induced; spinal dorsal; |

Downloaded from https://portlandpress.com/neuronalsignal/article-pdf/doi/10.1042/NS20190099/870875/ns-2019-0099c.pdf by guest on 07 April 2020
| miR     | Target Gene  | Function/Expression | Treatment | Animal | Species |
|---------|--------------|----------------------|-----------|--------|---------|
| miR-7a  | Scn2b        | Sodium voltage-gated channel beta subunit 2 | LucA | SNL   | DRG     | rat     | [86] |
| miR-7a  | Nefl         | Neurofilament light  | LucA | SNL   | DRG     | rat     | [87] |
| miR-9   | Foxp1        | Forkhead box P1      | mimic + WB sciatic nerve crush | DRG | mouse | [88] |
| miR-19a | Mecp2        | Methyl CpG binding protein 2 | LucA | SNI   | DRG     | mouse | [89] |
| miR-20b-5p | Akt3      | AKT serine/threonine kinase 3 | LucA | CCI   | spinal cord | rat | [90] |
| miR-21-5p | Timp3; Ccl1 | TIMP metalloproteinase inhibitor 3; C-C motif chemokine ligand 1 | LucA | CCI   | spinal cord | rat | [91] |
| miR-23a-3p | Cxcr4    | Chemokine (C-X-C motif) receptor 4 | LucA | SNL   | spinal cord | mouse | [92] |
| miR-23b | Nox4         | NADPH oxidase 4       | LucA | Traumatic SCI (neuropathic pain) | spinal cord | mouse | [93] |
| miR-26a-5p | Mapk6     | Mitogen-activated protein kinase 6 | LucA | CCI   | spinal cord | rat | [94] |
| miR-30b | Scn9a        | Sodium voltage-gated channel alpha subunit 9 | LucA | SNI   | DRG     | rat     | [95] |
| miR-30b | Scn3a        | Sodium voltage-gated channel alpha subunit 3 | LucA | SNL   | DRG     | rat     | [96] |
| miR-34a | Scn2b; Vamp2 | Sodium voltage-gated channel beta subunit 2; Vesicle-associated membrane protein 2 | LucA | CCI   | DRG     | rat | [97] |
| miR-34a | Xist; Yy1   | X inactive specific transcript; YY1 transcription factor | LucA | CRPS  | blood   | human | [58] |
| miR-34a | CRHR1       | Corticotropin releasing hormone receptor 1 | LucA | CRPS  | blood   | human | [54] |
| miR-34c | Nlrp3       | NLR family, pyrin domain containing 3 | LucA | CCI   | spinal cord | mouse | [98] |
| miR-96  | Scn3a       | Sodium voltage-gated channel alpha subunit 3 | mimic + WB | CCI | DRG     | rat | [99] |
| miR-101 | KPNB1       | Karyopherin subunit beta 1 | LucA | neuropathic pain patients | plasma / sural nerve | human | [59] |
| miR-127 | Mecp2       | Methyl CpG binding protein 2 | LucA | SNI   | DRG     | mouse | [89] |
| miR-141 | Hmgb1       | High mobility group box 1 | LucA | CCI   | DRG     | rat | [100] |
| miR-142-3p | Hmgb1  | High mobility group box 1 | LucA | SNL   | DRG     | mouse | [101] |
| miR-145 | Akt3        | AKT serine/threonine kinase 3 | LucA | CCI   | DRG     | rat | [102] |
| miR-145 | Rreb1       | Ras responsive element binding protein 1 | LucA | CCI   | spinal cord | rat | [103] |
| miR-182-5p | Ephb1    | Eph receptor B1       | LucA | CCI   | spinal cord | mouse | [104] |
| miR-183 | Mtor        | Mechanistic target of rapamycin kinase | LucA | CCI   | spinal cord | rat | [105] |
| miR-183 | Scn3a; Bdnf | Sodium voltage-gated channel alpha subunit 3; Brain-derived neurotrophic | mimic + qPCR | SNL | DRG     | rat | [106] |
| miR       | Regulator        | Target Gene                                                                 | Assay  | Tissue/Model  | Species | Reference |
|-----------|------------------|------------------------------------------------------------------------------|--------|---------------|---------|-----------|
| miR-183-5p| ↓ Kcnk2          | Potassium two pore domain channel subfamily K member 2 (Trek1)               | LucA   | CCI DRG       | rat     | [107]     |
| miR-186-5p| ↓ Cxcl13         | Chemokine (C-X-C motif) ligand 13                                            | LucA   | SNL spinal cord | mouse   | [108]     |
| miR-190a-5p| ↓ Slc17a6       | Solute carrier family 17 (sodium-dependent inorganic phosphate cotransporter), member 6 (Vglut2) | LucA   | diaberic neuropathy spinal cord | mouse | [109]     |
| miR-200b  | ↓ Zeb1           | Zinc finger E-box binding homeobox 1                                       | LucA   | CCI spinal cord / microglia | rat     | [110]     |
| miR-206   | ↓ Bdnf           | Brain-derived neurotrophic factor                                          | LucA   | CCI DRG       | rat     | [111]     |
| miR-206-3p| ↓ Hdac4          | Histone deacetylase 4                                                       | LucA   | CCI DRG       | rat     | [112]     |
| miR-301   | ↓ Mecp2          | Methyl CpG binding protein 2                                                | LucA   | SNI DRG       | mouse   | [89]      |
| miR-338-5p| ↓ Il6            | Interleukin 6                                                               | LucA   | CRPS plasma   | human   | [42]      |
| miR-362-3p| ↓ Pax2           | Paired box 2                                                                | LucA   | SCI spinal cord | rat     | [113]     |
| miR-429   | ↓ Zeb1           | Zinc finger E-box binding homeobox 1                                       | LucA   | CCI spinal cord / microglia | rat     | [110]     |
| miR-449a  | ↓ Trpa1; Kcnma1  | Transient receptor potential cation channel, subfamily A, member 1; Potassium large conductance calcium-activated channel, subfamily M, alpha member 1 | mimic + qPCR | SNI DRG       | mouse   | [114]     |
| miR-539   | ↓ Grin2b         | Glutamate ionotropic receptor NMDA type subunit 2B                           | mimic + WB | CCI ACC       | rat     | [115]     |
| miR-939   | ↓ VEGFA          | Vascular endothelial growth factor A                                        | LucA   | CRPS plasma   | human   | [53]      |

CCI: chronic constriction injury; CRPS: chronic regional pain syndrome; SCI: spinal cord injury; SNI: spared nerve injury; SNL: sciatic nerve ligation.

**Mechanisms of miRNA action.**

Intracellular miRNAs suppress gene expression through tightly regulated steps within the microprocessor complex: For this, the miRNA within the ‘activated’ RNA induced silencing complex (RISC) attaches to the 3'-untranslated region (UTR) of a given target mRNA primarily through its heptameric 5’ seed region (positions 2-8). One given mRNA harboring one or several miRNA binding sites in its 3’UTR can be regulated by various miRNAs. miRNA binding to the target gene’s miRNA recognition element (MRE) with full complementarity (which is rare in mammals) leads to destabilization and degradation (see also Fig. 1); if the complementarity is incomplete binding induces translational repression [116]. Protein expression may be downregulated, although mRNA levels may remain unaltered in case of incomplete complementarity. miRNAs regularly target a multitude of target genes at the same time and thus may regulate entire signaling networks within one cell. In addition to their regulated target mRNAs, miRNAs hybridize with pseudogenes or circular RNAs (circRNAs) acting as endogenous miRNA neutralizing sponges, which inhibit...
or limit intracellular miRNA effects [117]. An unconventional role of extracellular miRNAs for rapid excitation of nociceptor neurons has been discovered recently: miRNA-let-7b induces rapid inward currents and excitation of nociceptors. These responses require the GUUGUGU motif, only occur in neurons co-expressing TLR7 and TRPA1, and are abolished in mice lacking Tlr7 or Trpa1. Thus, extracellular miRNAs may in addition to their regulatory function act as aptamers with a role as pain mediators via activating TLR7/TRA1 in nociceptor neurons [118].

Since the first publication on analgesic miR-124 effects, miRNA regulation has attracted increasing attention in the pain field. However, the increasing number of reports raises the problem how expression patterns and mechanisms can be interpreted with a more global perspective. In order to warrant the highest degree of stringency, only miRNAs are addressed in this review based on publications validating miRNA expression together with direct regulation of target genes related to pain processing (Table 3).

**miRNAs deregulated in the peripheral nerve.** Only few studies address miRNAs in peripheral nerve tissue where axons, Schwann cells, connective tissue and cells of the vasculature and resident as well as transient immune cells can be possible sources (Figure 2). Upregulation of miR-132-3p may there target the ionotropic glutamate receptor AMPA type subunit 1 (Gria1) [55]. This has been identified as a microglial gene potentially linked to the maintenance of neuropathic pain [119]. Another upregulated miRNA, miR-183-5p, targets Claudin 1, a tight junction protein that maintains the blood brain/blood nerve barrier and is downregulated after nerve injury [79, 120]. Along these lines, downregulation of miR-101 by targeting Importin beta 1 (also known as Karyopherin beta 1, KPNB1) may release a brake on importin expression and augment the accessibility of axons to exosomal cargo as a mechanisms to foster nerve regeneration but possibly also for proalgesic factors [59, 121].

**miRNAs deregulated in the dorsal root and trigeminal ganglia.** miRNA expression in the dorsal root or trigeminal ganglia (Figure 2, Table 3) can be deregulated in various cell types, such as neurons, Schwann cells, resident or invading immune cells or even the vasculature. The most intensely studied sources are peptidergic and non-peptidergic primary afferent nociceptors. Conditional deletion of the miRNA-maturation enzyme Dicer exclusively in neurons expressing the nociceptor specific sodium channel Nav1.8 critically affects neuronal excitability [122] and increasing evidence suggests that several miRNAs directly or indirectly modulate neuron function (Table 3). Particular miRNAs are deregulated in peripheral neurons after nerve injury giving rise to deregulation of miRNA targeted ion channel and metabotropic receptor transcripts which presumably causes nociceptor dysfunction [118, 122-124].

The most intensely investigated miRNA in the DRG is presently miR-21 which is expressed in neurons and upregulated in several neuropathic pain models. Both intrathecal delivery of a miR-21-5p antagonist and conditional deletion of miR-21 in sensory neurons reduce neuropathic hypersensitivity [37]. As a new mechanism of action miR-21 cargo from neurons to immune cells via exosomes has been introduced recently: following capsaicin activation, miR-21-5p containing exosomes are released from cultured DRG and phagocytosed by macrophages in which the resulting increase in miR-21-5p levels promotes a pro-inflammatory phenotype. Both, upregulation and release of miR-21 contribute to sensory neuron-macrophage communication after damage to the peripheral nerve [37]. Since intrathecal miR-21 injection induces pain hypersensitivity in wildtype mice but not in mice with a global deletion of toll like receptor 8 (Tlr8−/−) the TLR8 receptor appears to act as a downstream effector of miR-21 to maintain neuropathic pain, however, a direct targeting of the Tlr8 gene has not been validated yet [125].

miR-18, miR-19a, miR-19b as well as mir-92 are also upregulated in neuropathic pain models and in turn downregulate potassium channels including Kcnal, Kcna4, Kcnc4, Kcnd3, Kcnq5 [74]. The suppression of potassium channels in general increases neuronal excitability and this may be a relevant mechanism causing nociceptor excitation and sensitisation [126, 127]. In line with the alterations towards hyperexcitability, several downregulated miRNAs targeting voltage-gated sodium channels may further
promote neuronal excitability by releasing the breaks on sodium channel expression: Two alpha subunits of voltage-gated sodium channels, Scn3a giving rise to Nav1.3 and Scn9a giving rise to pain-related Nav1.7, are targeted by the downregulated miRNAs miR-30b, miR-96 and miR-183, which very likely contributes to upregulation of the ion channel alpha subunits in neuropathic pain models [95, 96, 99, 106]. In addition, downregulated miR-7a and miR-34a targeting sodium voltage-gated channel beta subunit 2 (Scn2b) may be involved in improved trafficking of already formed alpha subunits [86, 97]. Furthermore, transducer channels, such as TRPA1, can occur as a consequence of miR-449a downregulation [114]. The only potential change counteracting these proalgesic alterations refers to the downregulated miR-183-5p which targets potassium channel Trek1, a two pore domain potassium channel subfamily member 2 (Kcnk2), which as a leak current keeps the membrane potential hyperpolarized [107]. The upregulation of this channel may counteract the break set on potassium channel expression by the miR-17-92 cluster.

Alterations in enzymatic activity, inflammatory signalling pathways and epigenetic regulators are amongst the mechanisms targeted by deregulated miRNAs in DRG. For example, miR-15b upregulation targets Beta-secretase 1 which may be involved in neuroprotective processes, whereas miR-145 downregulation appears to release the break on Akt3 which can be targeted by miR-15a or miR-20b-5p mimics to relieve neuropathic pain [73, 90, 102, 128]. Downregulation of miR-183 and miR-206 contributes to the upregulation of brain-derived neurotrophic factor (Bdnf) which is required for regenerative processes but also is an important pain modulator [106, 111, 129, 130] (for review see [131]). Finally, several downregulated miRNAs (miR-19a, miR-132, miR-301) appear to affect epigenetic regulatory pathways, such as Mecp2 or HDAC4 (via miR-206-3p), and dependent processes which are relevant contributors fueling pathological functions in the spinal dorsal horn but may also be relevant for dysfunction of primary afferent nociceptors [89, 112, 132-136].

miRNAs deregulated in the spinal cord. miR-124 was the first miRNA for which an analgesic action at spinal cord level was demonstrated and correlated with a shift in the M1/M2 microglial marker ratio towards an anti-inflammatory phenotype [137]. The functional consequences of miR-103 regulation of Cav1.2 calcium channels and intrinsic excitability of spinal projection neurons have also been demonstrated [124]. More evidence supporting miRNA analgesic effects emerge from mice intrathecally receiving miR-124 or miR-103, which are reported to prevent and treat persistent inflammatory and neuropathic pain [124, 137]. Despite the fact that these miRNA treatments reduced signatures of synaptic modification, neuroinflammation and microglial response, the full extent and the mechanisms of the analgesic effect are not fully understood to date [35, 124, 137, 138]. However, several miRNAs have been found deregulated in rodent pain models together, mainly in microglia, with validated downstream targets with a potential relevance to pain signalling (Figure 3).

Deregulated miRNAs in the spinal cord (Figure 3) can emerge from various sources, such as neurons, microglia, astroglia or even the vasculature. The most intensely investigated sources are microglia which react to maintained nociceptive input to the spinal cord with proliferation and a change in phenotype and activity (microgliosis). In microglia, a number of upregulated miRNA (miR-155, miR-218 and miR-221) can inhibit the expression of suppressors of cytokine signalling, such as Socs1, and may promote inflammatory signatures, such as microgliosis [78, 82, 83]. A novel regulator of microglia, Dual specificity phosphatase 5 (Dusp5) is regulated by miR-32-5p and this is involved in the regulation of neuroinflammatory processes, such as cytokine release in the spinal cord [76].

At the same time several miRNAs, such as miR-200b and miR-429, are downregulated in microglia after nerve injury, and Zeb1 (Zinc finger E-box binding homebox 1) has been identified as a target of these two miRNAs [110]. Zeb family members are essential for the developing nociceptors in the DRG [139]. ZEB1 overexpression regulates the microglia response after ischemic stroke and in turn inhibits the production of astrocytic CXCL1 which leads to a decline in neutrophil infiltration, thereby reducing CNS inflammation. This
suggests involvement of miR-200b and miR-429 suppression in the resolution of neurological injury [140]. In contrast, miR-21-5p targeting the chemokine Ccl1 [91], miR-23a-3p targeting Cxcr4 [92], miR-34 targeting Nlrp3 (NLR family, pyrin domain containing 3) [98], and miR-186-5p targeting Cxcl13 [108] are downregulated leading to increased expression of inflammatory mediators and an augmentation of inflammatory processes in the spinal cord. Other downregulated miRNAs (miR-145, miR-183) at the same time may release the suppression of key components affecting cell morphology and microglia function via transcription factor Rreb1 [103, 141] or mTOR [105, 142] together with miR-195 upregulation, which suppresses Autophagy related 14 (Atg14 [81]). These microRNAs appear to orchestrate spinal neuroinflammation related to neuropathic pain. Another negative-feedback regulator of the astrocyte-mediated inflammatory response to injury is miR-146a, which is upregulated in astrocytes following nerve injury, and targets TNF receptor-associated factor 6 (Traf6) [77, 143]. Persistent upregulation of Traf6 in spinal cord astrocytes in the late phase after nerve injury maintains neuropathic pain by integrating TNF-α and IL-1β signaling and activating the JNK/CCL2 pathway and increased miR-146a expression can set a brake to the neuroinflammatory component maintained by Traf6 [77, 144].

In addition, miRNAs are generated and act within neurons and there are several possible mechanisms for activity-dependent miRNA regulation: First, upon strong synaptic input, Ca2+ influx through NMDA receptors activates the Ca2+-dependent enzyme calpain which can liberate Dicer from postsynaptic densities and stimulate Dicer RNAse III activity to facilitate processing of pre-miRNAs into mature miRNAs (Figure 4) [145]. Second, increased intracellular Ca2+ can induce de novo miRNA transcription. Third: although less is known about the mechanism of miRNA degradation, another possible mechanism controlling mature miRNA expression may be the activity-dependent degradation of the RISC component MOV10 by the proteasome. However, it is still not sufficiently clear whether MOV10 degradation promotes the disassembly of RISC and thus augments the turnover of miRNAs (for review see [1]).

Of particular interest and importance in the spinal dorsal horn (SDH) are upregulated miRNAs targeting inhibitory ion channels, such as GABA or K+ channels. In the chronic constriction injury (CCI) model, miR-182-5p is downregulated and targets Ephb1 [104]. This is of particular interest, since ephrinB-EphB receptor signalling plays a critical role in induction and maintenance of neuropathic pain by regulating neural excitability and synaptic plasticity in the DRG and the SDH [146]. Upregulation of miR-449a via targeting peroxisome proliferator-activated receptor gamma (Pparg) and reduced Pparg expression can aggravate the increased neuroexcitability and neuroexcitotoxicity associated with neuropathic pain [84, 147]. Increased excitatory activity in SDH may be further fueled by the release of glutamate transporter Vglut2 (Slc17a6, Solute carrier family 17 member 6) expression and augmentation by downregulated miR-190a-5p [109, 148-150]. At the same time, glutamate decarboxylase 1 (Gad1) regulates GABA synthesis and transport [151], and reduced expression of Gad1 impairs the function of GABAergic synapses, which appears to be induced by upregulation of miR-500 [85]. The transcription factor Paired box 2 (Pax2) is necessary for the GABAergic differentiation [151] and a loss of SDH GABAergic interneurons causes reduced GABAergic tone which contributes to neuropathic pain [152]. Therefore, the downregulation of miR-362-3p targeting Pax2 may rather be a compensatory change to restore GABAergic signaling in the SDH [113]. These processes are further enhanced by the downregulation of three miRNAs (miR-20b-5p, miR-23 and miR-26a-5p) leading to the increased expression of the kinases Akt3, Nox4 and Mapk6 whose relevance for neuropathic pain is well accepted [90, 93, 94]. Together, miRNAs are emerging as major controllers of neuro-immune processes in the SDH by switching neurons as well as non-neuronal cells into proalgesic modes of action and supporting the development and maintenance of signatures supporting neuropathic pain at spinal cord level.

**miRNAs deregulated in the brain.** miRNAs act at the neuro-immune interface, which controls neuronal plasticity and memory but also are linked to the etiology of anxiety and mood disorders [13, 14, 35]. Deficits in the interaction of immune cells and neurons together with cognitive and emotional alterations
in patients with neuropathic or neurogenic pain syndromes are hypothesised to converge on ncRNA deregulated mechanisms along the entire neuraxis, and alterations in ncRNAs expression may account for the variation of susceptibility to certain types of pain or even for the responsiveness to analgesics and development of opioid tolerance [153].

As in the spinal cord, neuronal and non-neuronal cells contribute to potential disease specific miRNA patterns in brain regions that are relevant for the processing of painful stimuli. Brain specific miRNAs are emerging as regulators of cognition, neuronal plasticity and memory, regulating synapse structure and function, and specific miRNAs not only control cognition and emotional processes but also neuro-immune communication in the brain [14, 154]. In general, happiness, anxiety and depression seem to depend on miRNA expression levels and specific miRNAs are deregulated in depression, anxiety, and pre-clinical models of psychological stress. Moreover psychoactive agents, including antidepressants and mood stabilisers, utilise miRNAs as downstream effectors [13]. In the brain, AMPA-mediated synaptic transmission is reduced by neuronal over-expression of miR-125b and increased by miR-132 due to differential regulation of glutamate NR2A and NR2B receptor mRNA [155]. Other glutamate receptor subunits in the brain are regulated by dopamine through miR-181a, which has been associated with the pain system [156]. In particular, miR-132 is a highly interesting brain specific miRNA, since it is upregulated by BDNF and other growth factors in cortical neurons resulting in an increased expression of synaptic glutamate receptors NR2A, NR2B and GluR1 [157, 158]. In the hippocampus, miR-132 targets acetylcholinesterase and this is relevant for stress-induced cognitive deficits. In the amygdala miR-34 is associated with the repression of stress-induced anxiety [159, 160]. In neuropathic pain, maladaptive responses of the nucleus accumbens have been associated with deregulated miRNAs [67]. Endogenous pain control systems including GABAergic and opioidergic synaptic signals are downregulated by miRNAs, such as miR-134 or miR-181a, with some of them linking miRNAs like let-7 or miR-339 to opioid tolerance [161-164]. Despite the increasing number of reports, only few studies validate the deregulated miRNAs acting on specific target genes in the brain in neuropathic pain models (Figure 3). Downregulation of miR-539 can release the brake on the expression of Grin2b (Glutamate ionotopic receptor NMDA type subunit 2B) and enhance the formation of pain memory in the anterior cingulate cortex [115] and also in the brain stem, an upregulation of miR-195 and its target gene patched 1 (Ptc1) has been reported [80]. Altogether, although relevant roles for miRNA regulated processes in the pathogenesis of neuropathic pain can be anticipated also for relevant brain areas this field of pain research is still in its infancy.

Long ncRNAs
Synthesis and function
Long ncRNAs (lncRNAs) of more than 200 nucleotides are the second most studied group of ncRNAs. Currently 172’216 human and 131’697 mouse transcripts are annotated in the systematic database NONCODEv5 [165], whereas the curated knowledgebase LncBook documents 270’044 human lncRNAs [166]. Depending on their genomic location, lncRNA sequences can be intronic, natural antisense transcripts (NATs), sense, extrapolgenic, enhancer, promoter and bidirectional, and can have a linear or circular structure (circRNAs [167, 168]). lncRNA expression patterns highly depend on cell and tissue type as well as on developmental or disease states [169]. In general, lncRNA genes resemble protein coding genes, as their transcription follows similar rules [169, 170]. LncRNAs can be capped at their 5’ end, polyadenylated at their 3’ end, alternatively adenylated or not, and can undergo alternative splicing [167, 171]. Besides similar transcriptional mechanisms to protein coding genes, lncRNA biogenesis processes can include cleavage by ribonuclease P to form triple helical structures and the formation of circular structures [168]. Their localization in the nucleus, cytoplasm, mitochondria, ribosomes, extracellular membranes and exosomes defines and controls their functions in cellular processes, such as transcriptional, post-transcriptional and epigenetic regulation [169, 170, 172]. LncRNAs can act as decoys, competing endogenous RNAs (ceRNAs), guides, scaffolds and signals [167, 168, 173]. In the nucleus, lncRNAs can affect...
transcription via epigenetic mechanisms and chromatin remodeling as well as by stabilizing mRNA and changing mRNA splicing [173]. As decoys, lncRNAs can bind to proteins, such as transcription factors or RNA binding proteins, making them unavailable to perform their actions, which can result in transcriptional inhibition and mRNA degradation [167]. Furthermore, lncRNAs can act as competing endogenous RNA (ceRNA) sponging miRNAs and making them unavailable for interaction with their target-genome. In contrast to miRNAs, lncRNAs interact with single targets to up- or downregulate expression levels. Due to the various mechanisms of actions and the high number of lncRNAs, their precise functions and interconnections are not fully unveiled. Their implications in pain conditions have been addressed mostly in animal models, providing a firm indication on the importance of lncRNAs and circRNAs in the establishment and development of pain, however the precise mechanisms are not fully elucidated.

**IncRNAs as possible signatures for pain disorders**

IncRNAs are deregulated in diabetic peripheral neuropathy and CRPS [58, 138, 174-176], and similar to miRNAs, they can be detected in liquid biopsies (Table 4). The most studied IncRNA in DNP is NONRATT021972 which is upregulated in the serum and correlates with higher neuropathic pain scores, indicating its potential as a biomarker [138, 177]. Another upregulated ncRNA in type 2 diabetes mellitus and DNP serum is uc.48+ which is involved in purinergic receptors-mediated responses [75, 178]. Among 1'327 deregulated IncRNAs in the PBMCs of female patients with DNP, MALAT1, H19, PVT1 and MIR143HG could potentially qualify as biomarkers [174]. In female CRPS patients, XIST appears as a promising indicator of poor responsiveness to ketamine [58]. XIST acts as a ceRNA on miR-34a, thus enhancing expression levels of the transcription factor YY1 promoting XIST expression in an autoregulatory loop [58]. CircRNAs are much less studied in patients with neuropathic pain and currently there is only one study showing that circHIPK3 expression positively correlates with the severity of neuropathic pain in diabetic patients [176].

**Table 4:** Deregulated IncRNAs identified in liquid biopsies of patients with pain disorders.

| Disease              | Detection method | Sample type | Upregulation | Downregulation | deregulated IncRNA or circRNA | Reference |
|----------------------|------------------|-------------|--------------|----------------|-------------------------------|-----------|
| Diabetic neuropathy  | microarray       | PBMCs       | 256          | 1071           | MALAT1, H19, PVT1, MIR143HG   | [174]     |
| Diabetic neuropathy  | RT-qPCR          | serum       | 1            | na             | NONRATT021972                 | [138]     |
| Diabetic neuropathy  | RT-qPCR          | serum       | 1            | na             | uc.48+                        | [179]     |
| Diabetic neuropathy  | RT-qPCR          | serum       | 1            | na             | uc.48+                        | [178]     |
| Diabetic neuropathy  | RT-qPCR          | serum       | 1            | na             | circHIPK3                     | [176]     |
| CRPS in female patients | RT-qPCR    | whole blood | 1            | na             | XIST                          | [58]      |

**IncRNA tissue expression in animal models**

IncRNAs and circRNAs are differentially expressed in animal pain models in sciatic nerve, DRG and spinal cord [180-185]. Most of these studies combine IncRNA and mRNA expression analyses including complex bioinformatic pathways to generate networks of potential functional interactions [180, 186, 187], however only few have been explored using a more mechanistic approach (Table 5). Differential expression of IncRNAs upon peripheral nerve injuries is time-dependent and varies between strains and species [182, 183, 185]. LncRNAs play important roles in neuropathic pain processes not only in neurons, but also in non-neuronal cells, such as Schwann cells, satellite glial cells, macrophages and microglia [75, 84, 185, 188-191].
Table 5: Deregulated IncRNA and target genes related to neuropathic human pain disorders or preclinical models of neuropathic pain. For ethical reasons, bilateral CCI was excluded as a model.

| IncRNA     | Regulation | Target      | Gene description                           | Validation                  | Pain Model   | Tissue     | Species     | Mechanism                        | Reference |
|------------|------------|-------------|--------------------------------------------|-----------------------------|--------------|------------|-------------|----------------------------------|-----------|
| TUSC7      | ↓          | miR-449a    | microRNA 449a                              | RIP                         | SCI          | spinal cord| rat         | IncRNA:mRNA interaction          | [84]      |
| XIST       | ↑          | miR-34a     | microRNA 34a                               | LucA                        | CRPS; CFA-induced inflammation | whole blood | human; mouse | IncRNA:mRNA interaction          | [58]      |
| circHIPK3  | ↑          | miR-124     | microRNA 124                               | LucA/RNA pull down          | DNP          | serum; DRG | human; rat | IncRNA:mRNA interaction          | [176]     |

### Upregulation of target gene

| BC168687   | ↑          | Trpv1       | transient receptor potential vanilloid type 1 | siRNA/WB, immunostaining   | DPN          | DRG        | rat         | not specified                     | [192]     |
| BC168687   | ↑          | P2rx7       | purinergic receptor P2X 7                    | siRNA/RT-qPCR, WB, immunostaining | DNP          | satellite cells cultures | rat         | not specified                     | [191]     |
| BC168687   | ↑          | P2rx7       | purinergic receptor P2X 7                    | siRNA/WB, immunostaining   | DPN          | DRG        | rat         | not specified                     | [193]     |
| MRAK0097   | 13         | P2rx3       | purinergic receptor P2X 3                    | siRNA/WB, RIP, immunostaining | CCI          | DRG        | rat         | IncRNA:protein interaction       | [194]     |
| NONRATT0   | 21972      | P2rx3       | purinergic receptor P2X 3                    | siRNA/WB, immunostaining   | DPN          | DRG        | rat         | not specified                     | [177]     |
| NONRATT0   | 21972      | P2rx7       | purinergic receptor P2X 7                    | siRNA/WB, immunostaining   | DPN          | DRG        | rat         | IncRNA:mRNA interaction          | [195]     |
| PKIA-A51   | ↑          | CDK6        | cyclin dependent kinase 6                   | LucA; siRNA/WB; RIP         | SNL          | spinal cord | rat         | enhancement of promotor activity | [196]     |
| uc.48+     | ↑          | P2rx3       | purinergic receptor P2X 3                    | siRNA/WB, immunostaining   | DPN          | DRG        | rat         | not specified                     | [178]     |
| uc.48+     | ↑          | P2rx7       | purinergic receptor P2X 7                    | siRNA/WB, immunostaining; RIP | CCI-ION      | trigeminal ganglia | rat         | IncRNA:protein interaction       | [197]     |

### Downregulation of target gene

| Kcn2-NAT   | ↑          | Kcn2        | potassium voltage-gated channel subfamily A member 2 | overexpression, WB | SNL, CCI, sciatic nerve axotomy | DRG        | rat         | IncRNA:mRNA interaction          | [198]     |
| Eg2-NAT    | ↑          | Eg2         | early growth response 2                      | overexpression; anti-GapMers; ChiP; WB; RIP/WB | sciatic nerve injury | DRG; sciatic nerve | mouse | chromatin remodeling complex recruitment | [199]     |

**IncRNAs deregulated in the peripheral nerve.** Differential expression of IncRNAs and circRNAs in peripheral nerves in neuropathic pain models have not been addressed in detail. Dysregulated IncRNAs are reported in the sciatic nerve after a sciatic nerve crush [185]. This model is used to explore nerve regeneration and numerous differentially expressed IncRNAs were associated with inflammatory and immune responses, which could possibly be relevant for neuropathic pain [185]. Particularly, NONMMUG014387 enhances the proliferation of cultured mouse Schwann cells, presumably via cis-upregulation of collagen triple helix repeat containing 1 (Cthrc1) [185], whereas the antisense to the Eg2 promoter ncRNA (Eg2-antisense-RNA) downregulates Eg2 and promotes demyelination upon peripheral nerve injury by an epigenetic mechanism, in which a chromatin remodeling complex is assembled at the Eg2 promoter [199].

**IncRNAs deregulated in the dorsal root and trigeminal ganglia.** Differentially expressed IncRNAs and their functions are intensely studied in rodent neuropathic pain models, whereas circRNAs have not been addressed yet [200, 201]. IncRNAs downregulate voltage-gated channels and one of the first IncRNAs found...
to be implicated in pain is the endogenous voltage-gated potassium channel (Kv) Kcna2-antisense-RNA (NAT), which upon nerve injury is transcriptionally induced by myeloid zinc finger protein 1 (MZF1) and specifically targets and downregulates Kcna2, resulting in reduced potassium currents and increased DRG excitability [202]. Other upregulated lncRNAs, such as BC168687 [192, 193], MRAK009713 [194], NONRATT021972 [177, 178, 195] and uc.48+ [178, 179], contribute to mechanical hypersensitivity via cell-type specific interactions and induction of different purinergic receptors known for their pain modulating properties. For example, NONRATT021972 and uc.48+ upregulate the ionotropic purinoreceptor P2X3 in small-medium DRG neurons but P2X7 in satellite glia cells [177-179, 195]. BC168687 upregulates TRPV1 and MRAK009713 promotes the upregulation of P2X3 receptor in DRG neurons [192, 194]. Additionally, uc.48+ inhibition alleviates mechanical hypersensitivity in a rat model for trigeminal neuralgia, by inhibiting the expression of P2X7 receptor in glial cells within the trigeminal ganglia [203]. In addition, uc.48+ appears to exert inhibitory effects on neuroregeneration since inhibition of uc.127 enhances the outgrowth of DRG neurons in vitro [204].

**lncRNAs deregulated in the spinal cord and brain.** Most of the studies focus on whole spinal cord tissues and therefore do not distinguish between alterations occurring in neuronal and non-neuronal cells [183, 184, 205-208]. Nevertheless, the identification of dysregulated lncRNAs and circRNAs and the computational construction of interaction-networks between lncRNAs/circRNAs-miRNAs-mRNAs provide directions for future studies and potential therapeutic targets. Interestingly, not only SNI-induced mechanical hyperalgesia but also the differential expression of lncRNAs is alleviated by the tetracycline antibiotic minocycline [205]. Few lncRNAs have been functionally investigated at the spinal cord level. PK1A-AS1 overexpression enhances pain behaviors by demethylating the promoter region and promoting the expression of CDK6, an important component in neuroinflammation and neuropathic pain, whereas PK1A-AS1 downregulation exerts analgesic effects [196]. Of the lncRNAs that are downregulated after peripheral nerve injury, TUSC7 may be of particular mechanistic relevance, as its upregulation inhibits the activation of microglia by targeting miR-449a and increasing the expression of the miR-499a target gene PPAR-γ [84]. The only circRNA that has been functionally related to DPN is circHIPK3 which is upregulated in diabetic rats, acts as a miR-124 sponge and inhibition of circHIPK3 has analgesic and anti-inflammatory effects [176]. In contrast to the emerging role of lncRNAs in the spinal cord, their importance in pain processing brain areas has so far not been mechanistically addressed.

**Synopsis**

The field of ncRNAs is quickly expanding in the recent years and numerous studies have addressed and associated differentially expressed ncRNAs with neuropathic pain disorders in humans and their corresponding preclinical models. Against initial expectations, common miRNA candidates indicative of neuropathic pain in liquid biopsies have not emerged so far but lncRNAs may offer better perspectives. Whereas the suitability of miRNAs as clinically applicable biomarkers for pain disorders is still disputable, numerous studies have provided novel mechanistic insight into the role of miRNAs in the molecular sequelae involved in the pathogenesis of neuropathic pain along the entire pain pathway. Specific processes within neurons, immune cells, glia as the cellular components of the neuropathic pain triad and the communication paths between them are controlled by specific miRNAs in immune cells, neurons or glia. Therefore, nucleotide sequences mimicking or antagonizing miRNA actions can provide novel therapeutic strategies for pain treatment, provided their human homologues serve the same or at least similar functions. Similar clinical applications can be expected for tools targeting lncRNAs, which converge so far mainly on purinergic signaling pathways both in neurons and glia, and possibly even for other ncRNA species that have not been explored so far.
Figure legends:

Figure 1: Classical and alternative mechanisms of mature miRNA generation. The microRNA gene is transcribed into a primary microRNA (pri-miRNA) or mirtron by polymerase II (Pol II). Drosha together with the accessory protein DGCR8 cleaves the pri-miRNA into a pre-miRNA. Alternatively, the pre-miRNA can arise from alternative splicing of the mirtron. Pre-miRNA binds to Exportin5 for nuclear export. Within the cytoplasm, Dicer and Argonaute 2 (AGO) cleave off the hairpin structure to generate a duplex miRNA. The two strands separate and within the RNA silencing complex (RISC) and in the presence of AGO the mature miRNA hybridizes with complementary seed sequences (8 nucleotides length) of possible target RNA strands (adapted from [24, 25]). Depending on the degree of homology, the miRNA induces translational repression (incomplete match) or target mRNA degradation (full match, not in mammals) is induced.

Figure 2: Up- or downregulated miRNAs in peripheral nerve or sensory ganglia and their target genes which are associated with neuropathic pain. Akt3: AKT serine/threonine kinase 3; Bace1: Beta-secretase 1; Bdnf: Brain-derived neurotrophic factor; Dpp10: Dipeptidyl peptidase like 10; Foxp1: Forkhead box P1; Hdac4: Histone deacetylase 4; Hmgb1: High mobility group box 1; Kcn1a: Potassium voltage-gated channel subfamily A member 1; Kcn4a: Potassium voltage-gated channel subfamily A member 4; Kcn3d: Potassium voltage-gated channel subfamily D member 3; Kcnk2: Potassium two pore domain channel subfamily K member 2 (Trek1); Kcnma1: Potassium large conductance calcium-activated channel, subfamily M, alpha member 1; Kcnq4: Potassium voltage-gated channel subfamily C member 4; Kcnq5: Potassium voltage-gated channel subfamily Q member 5; Mepc2: Methyl CpG binding protein 2; Nefl: Neurofilament light; Scn1b: Sodium voltage-gated channel beta subunit 1; Scn2b: Sodium voltage-gated channel beta subunit 2; Scn3a: Sodium voltage-gated channel alpha subunit 3; Scn9a: Sodium voltage-gated channel alpha subunit 9; Trpa1: Transient receptor potential cation channel, subfamily A, member 1; Vamp2: Vesicle-associated membrane protein 2. Scale bars: 100 µm (micrographs were kindly provided by M. Langeslag)

Figure 3: Deregulated miRNA in spinal cord and brain with the respective associated target genes. Although specific brain areas are involved in different aspects of processing pain perception, miRNA expression so far has not been addressed specifically within these areas under neuropathic pain conditions. Akt3: AKT serine/threonine kinase 3; Atg14: Autophagy related 14; Dusp5: Dual specificity phosphatase ; Ccl1: C-C motif chemokine ligand 1; Cxcl13: Chemokine (C-X-C motif) ligand 13; Cxcr4: Chemokine (C-X-C motif) receptor 4 ; Ephb1: Eph receptor B1; Gad1: Glutamate decarboxylase 1; Grin2b: Glutamate ionotropic receptor NMDA type subunit 2B; Mapk6: Mitogen-activated protein kinase 6; Mtor: Mechanistic target of rapamycin kinase; Nlrp3: NLR family, pyrin domain containing 3; Nox4: NADPH oxidase 4; Pax2: Paired box 2; Ppara: Peroxisome proliferator-activated receptor gamma; Ptc1: Patched 1; Rreb1: Ras responsive element binding protein 1; Slc17a6: Solute carrier family 17 (sodium-dependent inorganic phosphate cotransporter); Socs1: Suppressor of cytokine signaling 1; Socs3: Suppressor of cytokine signaling 3; Timp3: TIMP metalloproteinase inhibitor 3; Traf6: TNF receptor-associated factor 6; Zeb1: Zinc finger E-box binding homeobox 1

Figure 4: Activity dependent generation of miRNA in neurons affecting synapse specific protein synthesis (adapted from [1])
Neuronal Signaling. This is an Accepted Manuscript. You are encouraged to use the Version of Record that, when published, will replace this version. The most up-to-date version is available at https://doi.org/10.1042/NS20190099

Nawroth, P. P. (2012) Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy. Nature medicine. 18, 926-933

Goebel, A. (2011) Complex regional pain syndrome in adults. Rheumatology (Oxford, England). 50, 1739-1750

Mutso, A. A., Radzicki, D., Baliki, M. N., Huang, L., Banisadr, G., Centeno, M. V., Radulovic, J., Martina, M., Miller, R. J. and Apkarian, A. V. (2012) Abnormalities in hippocampal functioning with persistent pain. The Journal of neuroscience : the official journal of the Society for Neuroscience. 32, 5747-5756

Cardoso, A. L., Guedes, J. R. and de Lima, M. C. (2016) Role of microRNAs in the regulation of innate immune cells under neuroinflammatory conditions. Current opinion in pharmacology. 26, 1-9

Ha, M. and Kim, V. N. (2014) Regulation of microRNA biogenesis. Nature reviews. Molecular cell biology. 15, S09-524

Treiber, T., Treiber, N. and Meister, G. (2019) Regulation of microRNA biogenesis and its crosstalk with other cellular pathways. Nature reviews. Molecular cell biology. 20, 5-20

Lee, Y., Jeon, K., Lee, J. T., Kim, S. and Kim, V. N. (2002) MicroRNA maturation: stepwise processing and subcellular localization. The EMBO journal. 21, 4663-4670

Han, J., Lee, Y., Yeom, K. H., Kim, Y. K., Jin, H. and Kim, V. N. (2004) The Drosha-DGCR8 complex in primary microRNA processing. Genes & development. 18, 3016-3027

Lee, Y., Ahn, C., Han, J., Choi, H., Kim, J., Yim, J., Lee, J., Provost, P., Radmark, O., Kim, S. and Kim, V. N. (2003) The nuclear RNase III Drosha initiates microRNA processing. Nature. 425, 415-419

Melamed, Z., Levy, A., Ashwal-Fluss, R., Lev-Maor, G., Mekahel, K., Atlas, N., Gilad, S., Shanar, R., Levy, C., Kadener, S. and Ast, G. (2013) Alternative splicing regulates biogenesis of miRNAs located across exon-intron junctions. Molecular cell. 50, 869-881

Alexiou, P., Vergoulis, T., Gleditzsch, M., Prekas, G., Dalamagas, T., Megraw, M., Grosse, I., Sellis, T. and Hatzigeorgiou, A. G. (2010) miRGen 2.0: a database of microRNA genomic information and regulation. Nucleic acids research. 38, D137-141

Zeidler, M., Hütttenhofer, A., Kress, M. and Kummer, K. K. (under review) Intragenic microRNAs autoregulate their host genes in both direct and indirect ways - a cross-species analysis.

Godnic, I., Zorc, M., Jevsinek Skok, D., Calin, G. A., Horvat, S., Dovc, P., Kovac, M. and Kunej, T. (2013) Genome-wide and species-wide in silico screening for intragenic MicroRNAs in human, mouse and chicken. PloS one. 8, e65165

Franca, G. S., Vibranovski, M. D. and Galante, P. A. (2016) Host gene constraints and genomic context impact the expression and evolution of human microRNAs. Nature communications. 7, 11438

Hori, N., Narita, M., Yamashita, A., Horiuchi, H., Hamada, Y., Kondo, T., Watanabe, M., Igarashi, K., Kawata, M., Shibasaki, M., Yamazaki, M., Kuzumaki, N., Inada, E., Ochiya, T., Iseki, M., Mori, T. and Narita, M. (2016) Changes in the expression of IL-6-Mediated MicroRNAs in the dorsal root ganglion under neuropathic pain in mice. Synapse (New York, N.Y.). 70, 317-324

Brites, D. and Fernandes, A. (2015) Neuroinflammation and Depression: Microglia Activation, Extracellular Microvesicles and microRNA Dysregulation. Frontiers in cellular neuroscience. 9, 476

Rao, P., Benito, E. and Fischer, A. (2013) MicroRNAs as biomarkers for CNS disease. Frontiers in molecular neuroscience. 6, 39

Simeoli, R., Montague, K., Jones, H. R., Castaldi, L., Chambers, D., Kelleher, J. H., Vacc, V., Pitcher, T., Grist, J., Al-Ahdaal, H., Wong, L. F., Perretti, M., Lai, J., Mouritzen, P., Pepper, P. and Mancagno, M. (2017) Exosomal cargo including microRNA regulates sensory neuron to macrophage communication after nerve trauma. Nature communications. 8, 1778

Ajit, S. K. (2012) Circulating microRNAs as biomarkers, therapeutic targets, and signaling molecules. Sensors (Basel, Switzerland). 12, 3359-3369

Orlova, I. A., Alexander, G. M., Qureshi, R. A., Sacan, A., Graziano, A., Barrett, J. E., Schwartzman, R. J. and Ajit, S. K. (2011) MicroRNA modulation in complex regional pain syndrome. Journal of translational medicine. 9, 195

McDonald, M. K., Tian, Y., Qureshi, R. A., Gormley, M., Ertel, A., Gao, R., Aradillas Lopez, E., Alexander, G. M., Sacan, A., Fortina, P. and Ajit, S. K. (2014) Functional significance of macrophage-derived exosomes in inflammation and pain. Pain. 155, 1527-1539

Douglas, S. R., Shenoda, B. B., Qureshi, R. A., Sacan, A., Alexander, G. M., Perreault, M., Barrett, J. E., Aradillas-Lopez, E., Schwartzman, R. J. and Ajit, S. K. (2015) Analgesic Response to Intravenous Ketamine
Is Linked to a Circulating microRNA Signature in Female Patients With Complex Regional Pain Syndrome.
The journal of pain : official journal of the American Pain Society. 16, 814-824
Ramanathan, S., Douglas, S. R., Alexander, G. M., Shenoda, B. B., Barrett, J. E., Aradillas, E., Sacan, A. and Ajit, S. K. (2019) Exosome microRNA signatures in patients with complex regional pain syndrome undergoing plasma exchange. Journal of translational medicine. 17, 81
Pasquier, J., Ramachandran, V., Abu-Qaoud, M. R., Thomas, B., Benurwar, M. J., Chidic, O., Hoarau-Vechot, J., Robay, A., Fakhr, K., Menzies, R. A., Jayyousi, A., Zirie, M., Al Suwaidi, J., Malik, R. A., Talal, T. K., Najafi-Shoushtari, S. H., Rafii, A. and Ab Khalil, C. (2018) Differentially expressed circulating microRNAs in the development of acute diabetic Charcot foot. Epigenomics. 10, 1267-1278
Cheng, B., Li, J. Y., Li, X. C., Wang, X. F., Wang, Z. J., Liu, J. and Deng, A. P. (2018) MiR-323b-5p acts as a novel diagnostic biomarker for critical limb ischemia in type 2 diabetic patients. Scientific reports. 8, 15080
Li, J. Y., Cheng, B., Wang, X. F., Wang, Z. J., Zhang, H. M., Liu, S. F., Chen, L. S., Huang, W. J., Liu, J. and Deng, A. P. (2018) Circulating MicroRNA-4739 May Be a Potential Biomarker of Critical Limb Ischemia in Patients with Diabetes. BioMed research international. 2018, 4232794
Santos-Bezerra, D. P., Santos, A. S., Guimaraes, G. C., Admoni, S. N., Perez, R. V., Machado, C. G., Pelaes, T. S., Passarelli, M., Machado, U. F., Queiroz, M. S., da Silva, M. E. R. and Correa-Giannella, M. L. (2019) Micro-RNAs 518d-3p and 618 Are Upregulated in Individuals With Type 1 Diabetes With Multiple Microvascular Complications. Frontiers in endocrinology. 10, 385
Alles, J., Fehlmann, T., Fischer, U., Backes, C., Galata, V., Minet, M., Hart, M., Abu-Halima, M., Grassner, F. A., Lenhof, H. P., Keller, A. and Meese, E. (2019) An estimate of the total number of true human miRNAs. Nucleic acids research. 47, 3353-3364
Git, A., Dvinge, H., Salmon-Divon, M., Osborne, M., Kutter, C., Hadfield, J., Bertone, P. and Caldas, C. (2010) Systematic comparison of microarray profiling, real-time PCR, and next-generation sequencing technologies for measuring differential microRNA expression. RNA (New York, N.Y.). 16, 991-1006
Hitzemann, R., Bottomly, D., Darakjian, P., Walter, N., Iancu, O., Searles, R., Wilmot, B. and McWeeney, S. (2013) Genes, behavior and next-generation RNA sequencing. Genes, brain, and behavior. 12, 1-12
Kalpachidou, T., Kummer, K. K., Mitric, M. and Kress, M. (2019) Tissue Specific Reference Genes for MicroRNA Expression Analysis in a Mouse Model of Peripheral Nerve Injury. Frontiers in molecular neuroscience. 12, 283
Herskovits, A. Z. and Guarente, L. (2014) SIRT1 in neurodevelopment and brain senescence. Neuron. 81, 471-483
Heyn, J., Luchting, B., Hinske, L. C., Hubner, M., Azad, S. C. and Kreth, S. (2016) miR-124a and miR-155 enhance differentiation of regulatory T cells in patients with neuropathic pain. Journal of neuroinflammation. 13, 248
McDonald, M. K., Ramanathan, S., Touati, A., Zhou, Y., Thanawala, R. U., Alexander, G. M., Sacan, A. and Ajit, S. K. (2016) Regulation of proinflammatory genes by the circulating microRNA hsa-mir-939. Scientific reports. 6, 30976
Shenoda, B. B., Alexander, G. M. and Ajit, S. K. (2016) Hsa-miR-34a mediated repression of corticotrophin releasing hormone receptor 1 regulates pro-opiomelanocortin expression in patients with complex regional pain syndrome. Journal of translational medicine. 14, 64
Leinders, M., Uceyler, N., Pritchard, R. A., Sommer, C. and Sorkin, L. S. (2016) Increased miR-132-3p expression is associated with chronic neuropathic pain. Experimental neurology. 283, 276-286
Li, Y. B., Wu, Q., Liu, J., Fan, Y. Z., Yu, K. F. and Cai, Y. (2017) miR199a3p is involved in the pathogenesis and progression of diabetic neuropathy through downregulation of SerpinE2. Molecular medicine reports. 16, 2417-2424
Asahchop, E. L., Branton, W. G., Krishnan, A., Chen, P. A., Yang, D., Kong, L., Zochodne, D. W., Brew, B. J., Gill, M. J. and Power, C. (2018) HIV-associated sensory polyneuropathy and neuronal injury are associated with miRNA-455-3p induction. JCI insight. 3
Shenoda, B. B., Tian, Y., Alexander, G. M., Aradillas-Lopez, E., Schwartzman, R. J. and Ajit, S. K. (2018) miR-34a-mediated regulation of XIST in female cells under inflammation. Journal of pain research. 11, 935-945
Liu, J. C., Xue, D. F., Wang, X. Q., Ai, D. B. and Qin, P. J. (2019) MIR-101 relates to chronic peripheral neuropathic pain through targeting KPNB1 and regulating NF-kappaB signaling. The Kaohsiung journal of medical sciences. 35, 139-145

Aldrich, B. T., Frakes, E. P., Kasuya, J., Hammond, D. L. and Kitamoto, T. (2009) Changes in expression of sensory organ-specific microRNAs in rat dorsal root ganglia in association with mechanical hypersensitivity induced by spinal nerve ligation. Neuroscience. 164, 711-723

Bai, G., Ambalavanan, R., Wei, D. and Dessem, D. (2007) Downregulation of selective microRNAs in trigeminal ganglion neurons following inflammatory muscle damage. Molecular pain. 3, 15

Bali, K. K., Hackenberg, M., Lubin, A., Kuner, R. and Devor, M. (2014) Sources of individual variability: miRNAs that predispose to neuropathic pain identified using genome-wide sequencing. Molecular pain. 10, 22

Kusuda, R., Cadetti, F., Ravanelli, M. I., Sousa, T. A., Zanon, S., De Luca, F. L. and Lucas, G. (2011) Differential expression of microRNAs in mouse pain models. Molecular pain. 7, 17

Norcini, M., Sideris, A., Martin Hernandez, L. A., Zhang, J., Blanck, T. J. and Recio-Pinto, E. (2014) An approach to identify microRNAs involved in neuropathic pain following a peripheral nerve injury. Frontiers in neuroscience. 8, 266

von Schack, D., Agostino, M. J., Murray, B. S., Li, Y., Reddy, P. S., Chen, J., Choe, S. E., Strassle, B. W., Li, C., Bates, B., Zhang, L., Hu, H., Kottis, S., Bingham, B., Liu, W., Whiteside, G. T., Samad, T. A., Kennedy, J. D. and Ajit, S. K. (2011) Dynamic changes in the microRNA expression profile reveal multiple regulatory mechanisms in the spinal nerve ligation model of neuropathic pain. PLoS one. 6, e17670

Poh, K. W., Yeo, J. F. and Ong, W. Y. (2011) MicroRNA changes in the mouse prefrontal cortex after inflammatory pain. European journal of pain (London, England). 15, 801.e801-812

Imai, S., Saeki, M., Yanase, M., Horiiuchi, H., Abe, M., Narita, M., Kuzumaki, N., Suzuki, T. and Narita, M. (2011) Change in microRNAs associated with neuronal adaptive responses in the nucleus accumbens under neuropathic pain. The Journal of neuroscience : the official journal of the Society for Neuroscience. 31, 15294-15299

Cao, S., Yuan, J., Zhang, D., Wen, S., Wang, J., Li, Y. and Deng, W. (2019) Transcriptome Changes In Dorsal Spinal Cord Of Rats With Neuropathic Pain. Journal of pain research. 12, 3013-3023

Malcangio, M. (2019) Role of the immune system in neuropathic pain. Scandinavian journal of pain. 70

Dai, D., Wang, J., Jiang, Y., Yuan, L., Lu, Y., Zhang, A., Zou, D. and Chen, X. (2019) Small RNA sequencing reveals microRNAs related to neuropathic pain in rats. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas. 52, e8380

Li, H., Wan, H. Q., Zhao, H. J., Luan, S. X. and Zhang, C. G. (2019) Identification of candidate genes and miRNAs associated with neuropathic pain induced by spared nerve injury. International journal of molecular medicine. 44, 1205-1218

Sommer, C., Leinders, M. and Uceyler, N. (2018) Inflammation in the pathophysiology of neuropathic pain. Pain. 159, 595-602

Ito, N., Sakai, A., Miyake, N., Maruyama, M., Iwasaki, H., Miyake, K., Okada, T., Sakamoto, A. and Suzuki, H. (2017) miR-15b mediates oxaliplatin-induced chronic neuropathic pain through BACE1 downregulation. British journal of pharmacology. 174, 386-395

Sakai, A., Saitow, F., Maruyama, M., Miyake, N., Miyake, K., Shimada, T., Okada, T. and Suzuki, H. (2017) MicroRNA cluster miR-17-92 regulates multiple functionally related voltage-gated potassium channels in chronic neuropathic pain. Nature communications. 8, 16079

Wu, H., Wen, F., Jiang, M., Liu, Q. and Nie, Y. (2018) LncRNA uc.48+ is involved in the diabetic immune and inflammatory responses mediated by P2X7 receptor in RAW264.7 macrophages. International journal of molecular medicine. 42, 1152-1160

Yan, T., Zhang, F., Sun, C., Sun, J., Wang, Y., Xu, X., Shi, J. and Shi, G. (2018) miR-32-5p-mediated Dusp5 downregulation contributes to neuropathic pain. Biochem Biophys Res Commun. 495, 506-511

Lu, Y., Cao, D. L., Jiang, B. C., Yang, T. and Gao, Y. J. (2015) MicroRNA-146a-5p attenuates neuropathic pain by suppressing TRAF6 signaling in the spinal cord. Brain Behav Immun. 49, 119-129

Tan, Y., Yang, J., Xiang, K., Tan, Q. and Guo, Q. (2015) Suppression of microRNA-155 attenuates neuropathic pain by regulating SOCS1 signalling pathway. Neurochem Res. 40, 550-560

Yang, S., Krug, S. M., Heitmann, J., Hu, L., Reinhold, A. K., Sauer, S., Bosten, J., Sommer, C., Fromm, M., Brack, A. and Rittner, H. L. (2016) Analgesic drug delivery via recombinant tissue plasminogen activator and microRNA-183-triggered opening of the blood-nerve barrier. Biomaterials. 82, 20-33
Neuronal Signaling. This is an Accepted Manuscript. You are encouraged to use the Version of Record that, when published, will replace this version. The most up-to-date version is available at https://doi.org/10.1042/NS20190099.

Inhibition of MicroRNA-195 Alleviates Neuropathic Pain by Targeting Patched1 and Inhibiting SHH Signaling Pathway Activation. Neurochem Res. 44, 1690-1702.

Shi, G., Shi, J., Liu, K., Liu, N., Wang, Y., Fu, Z., Ding, J., Jia, L. and Yuan, W. (2013) Increased miR-195 aggravates neuropathic pain by inhibiting autophagy following peripheral nerve injury. Glia. 61, 504-512.

Li, L. and Zhao, G. (2016) Downregulation of microRNA-218 relieves neuropathic pain by regulating suppressor of cytokine signaling 3. International journal of molecular medicine. 37, 851-858.

Xia, L., Zhang, Y. and Dong, T. (2016) Inhibition of MicroRNA-221 Alleviates Neuropathic Pain Through Targeting Suppressor of Cytokine Signaling 1. J Mol Neurosci. 59, 411-420.

You, Y., Zhu, M., Zhao, Y., Xu, M. and Qiu, M. (2018) Overexpression of TUSC7 inhibits the inflammation caused by microglia activation via regulating miR-449a/PPAR-gamma. Biochem Biophys Res Commun. 503, 1020-1026.

Huang, Z. Z., Wei, J. Y., Ou-Yang, H. D., Li, D., Xu, T., Wu, S. L., Zhang, X. L., Liu, C. C., Ma, C. and Xin, W. J. (2016) mir-500-Mediated GAD67 Downregulation Contributes to Neuropathic Pain. The Journal of neuroscience : the official journal of the Society for Neuroscience. 36, 6321-6331.

Sakai, A., Saitow, F., Miyake, N., Miyake, K., Shimada, T. and Suzuki, H. (2013) miR-7a alleviates the maintenance of neuropathic pain through regulation of neuronal excitability. Brain. 136, 2738-2750.

Yang, F. R., Chen, J., Yi, H., Peng, L. Y., Hu, X. L. and Guo, Q. L. (2019) MicroRNA-7a ameliorates neuropathic pain in a rat model of spinal nerve ligation via the neurofilament light polypeptide-dependent signal transducer and activator of transcription signaling pathway. Molecular pain. 15, 1744806919842464.

Jiang, J., Hu, Y., Zhang, B., Shi, Y., Zhang, J., Wu, X. and Yao, P. (2017) MicroRNA-9 regulates mammalian axon regeneration in peripheral nerve injury. Molecular pain. 13, 1744806917711612.

Manners, M. T., Tian, Y., Zhou, Z. and Ajit, S. K. (2015) MicroRNAs downregulated in neuropathic pain regulate MeCP2 and BDNF related to pain sensitivity. FEBS Open Bio. 5, 733-740.

You, H., Zhang, L., Chen, Z., Liu, W., Wang, H. and He, H. (2019) MiR-20b-5p relieves neuropathic pain by targeting Akt3 in a chronic constriction injury rat model. Synapse (New York, N.Y.). 73, e221225.

Zhong, L., Xiao, W., Wang, F., Liu, J. and Zhi, L. J. (2019) miR-21-5p inhibits neuropathic pain development via directly targeting C-C motif ligand 1 and tissue inhibitor of metalloproteinase-3. J Cell Biochem. 120, 16614-16623.

Pan, Z., Shan, Q., Gu, P., Wang, X. M., Tai, L. W., Sun, M., Luo, X., Sun, L. and Cheung, C. W. (2018) miRNA-23a/CXCR4 regulates neuropathic pain via directly targeting TXNIP/NLRP3 inflammasome axis. Journal of neuroinflammation. 15, 29.

Im, Y. B., Lee, Y., Kim, M. K., Han, I., Cho, H. T., Kwon, O. H. and Kang, S. K. (2012) Molecular targeting of NOX4 for neuropathic pain after traumatic injury of the spinal cord. Cell Death Dis. 3, e426.

Zhang, Y., Su, Z., Liu, H. L., Li, L., Wei, M., Ge, D. J. and Zhang, Z. J. (2018) Effects of miR-26a-5p on neuropathic pain development by targeting MAPK6 in in CCI rat models. Biomed Pharmacother. 107, 644-649.

Shao, J., Cao, J., Wang, J., Ren, X., Su, S., Li, M., Li, Z., Zhao, Q. and Zang, W. (2016) MicroRNA-30b regulates expression of the sodium channel Nav1.7 in nerve injury-induced neuropathic pain in the rat. Molecular pain. 12.

Su, S., Shao, J., Zhao, Q., Ren, X., Cai, W., Li, L., Bai, Q., Chen, X., Xu, B., Wang, J., Cao, J. and Zang, W. (2017) MiR-30b Attenuates Neuropathic Pain by Regulating Voltage-Gated Sodium Channel Nav1.3 in Rats. Frontiers in molecular neuroscience. 10, 126.

Brandenburger, T., Johannsen, L., Prassek, V., Kuebart, A., Raile, J., Wohlfromm, S., Kohrer, K., Huhn, R., Hollmann, M. W. and Hermanns, H. (2019) MiR-34a is differentially expressed in dorsal root ganglia in a rat model of chronic neuropathic pain. Neurosci Lett. 708, 134365.

Xu, L., Wang, Q., Jiang, W., Yu, S. and Zhang, S. (2019) MiR-34c Ameliorates Neuropathic Pain by Targeting NLRP3 in a Mouse Model of Chronic Constriction Injury. Neuroscience. 399, 125-134.

Chen, H. P., Zhou, W., Kang, L. M., Yan, H., Zhang, L., Xu, B. H. and Cai, W. H. (2014) Intrathecal miR-96 inhibits Nav1.3 expression and alleviates neuropathic pain in rat following chronic constriction injury. Neurochem Res. 39, 76-83.

Zhang, J., Zhang, H. and Zi, T. (2015) Overexpression of microRNA-141 relieves chronic constriction injury-induced neuropathic pain via targeting high-mobility group box 1. International journal of molecular medicine. 36, 1433-1439.
Zhang, Y., Mou, J., Cao, L., Zhen, S., Huang, H. and Bao, H. (2018) MicroRNA-142-3p relieves neuropathic pain by targeting high mobility group box 1. International journal of molecular medicine. 41, 501-510

Shi, J., Jiang, K. and Li, Z. (2018) MiR-145 ameliorates neuropathic pain via inhibiting inflammatory responses and mTOR signaling pathway by targeting Akt3 in a rat model. Neurosci Res. 134, 10-17

Pang, X., Tang, Y. and Zhang, D. (2016) Role of miR-145 in chronic constriction injury in rats. Exp Ther Med. 12, 4121-4127

Zhou, X., Zhang, C., Zhang, C., Peng, Y., Wang, Y. and Xu, H. (2017) MicroRNA-182-5p Regulates Nerve Injury-induced Noctive Hypersensitivity by Targeting Ephrin Type-b Receptor 1. Anesthesiology. 126, 967-977

Xie, X., Ma, L., Xi, K., Zhang, W. and Fan, D. (2017) MicroRNA-183 Suppresses Neuropathic Pain and Expression of AMPA Receptors by Targeting mTOR/VEGF Signaling Pathway. Cell Physiol Biochem. 41, 181-192

Lin, C. R., Chen, K. H., Yang, C. H., Huang, H. W. and Sheen-Chen, S. M. (2014) Intrathecal miR-183 delivery suppresses mechanical allodynia in mononeuropathic rats. Eur J Neurosci. 39, 1682-1689

Shi, D. N., Yuan, Y. T., Ye, D., Kang, L. M., Wen, J. and Chen, H. P. (2018) MiR-183-5p Alleviates Chronic Constriction Injury-Induced Neuropathic Pain Through Inhibition of TREK-1. Neurochem Res. 43, 1143-1149

Jiang, B. C., Cao, D. L., Zhang, Z. J., He, L. N., Li, C. H., Zhang, W. W., Wu, X. B., Berta, T., Ji, R. R. and Gao, Y. J. (2016) CXCL13 drives spinal astrocyte activation and neuropathic pain via CXCR5. J Clin Invest. 126, 745-761

Yang, D., Yang, Q., Wei, X., Liu, Y., Ma, D., Li, J., Wan, Y. and Luo, Y. (2017) The role of miR-190a-5p contributes to diabetic neuropathic pain via targeting SLC17A6. Journal of pain research. 10, 2395-2403

Yan, X. T., Zhao, Y., Cheng, X. L., He, X. H., Wang, Y., Zheng, W. Z., Chen, H. and Wang, Y. L. (2018) Inhibition of miR-200b/miR-429 contributes to neuropathic pain development through targeting zinc finger E box binding protein-1. J Cell Physiol. 233, 4815-4824

Sun, W., Zhang, L. and Li, R. (2017) Overexpression of miR-206 ameliorates chronic constriction injury-induced neuropathic pain in rats via the MEK/ERK pathway by targeting brain-derived neurotrophic factor. Neurosci Lett. 646, 68-74

Wen, J., He, T., Qi, F. and Chen, H. (2019) MiR-206-3p alleviates chronic constriction injury-induced neuropathic pain through targeting HDAC4. Exp Anim. 68, 213-220

Hu, Y., Liu, Q., Zhang, M., Yan, Y., Yu, H. and Ge, L. (2019) MicroRNA-362-3p attenuates motor deficit following spinal cord injury via targeting paired box gene 2. J Integr Neurosci. 18, 57-64

Lu, S., Ma, S., Wang, Y., Huang, T., Zhu, Z. and Zhao, G. (2017) MUS musculus-microRNA-449a ameliorates neuropathic pain by decreasing the level of KCNMA1 and TRPA1, and increasing the level of TPT1. Molecular medicine reports. 16, 353-360

Ding, M., Shen, W. and Hu, Y. (2017) The Role of miR-539 in the Anterior Cingulate Cortex in Chronic Neuropathic Pain. Pain Med. 18, 2433-2442

Goldie, B. J. and Cairns, M. J. (2012) Post-transcriptional trafficking and regulation of neuronal gene expression. Mol Neurobiol. 45, 99-108

Hansen, T. B., Jensen, T. I., Clausen, B. H., Bramsen, J. B., Finsen, B., Damgaard, C. K. and Kjems, J. (2013) Natural RNA circles function as efficient microRNA sponges. Nature. 495, 384-388

Park, C. K., Xu, Z. Z., Berta, T., Han, Q., Chen, G., Liu, X. J. and Ji, R. R. (2014) Extracellular microRNAs activate nociceptor neurons to elicit pain via TLR7 and TRPA1. Neuron. 82, 47-54

Jeong, H., Na, Y. J., Lee, K., Kim, Y. H., Lee, Y., Kang, M., Jiang, B. C., Yeom, Y. I., Wu, L. J., Gao, Y. J., Kim, J. and Oh, S. B. (2016) High-resolution transcriptome analysis reveals neuropathic pain gene-expression signatures in spinal microglia after nerve injury. Pain. 157, 964-976

Reinhold, A. K., Schwabe, J., Lux, T. J., Salvador, E. and Rittner, H. L. (2018) Quantitative and Microstructural Changes of the Blood-Nerve Barrier in Peripheral Neuropathy. Frontiers in neuroscience. 12, 936

Hervara, A., De Virgiliis, F., Palmisano, I., Zhou, L., Tantardini, E., Kong, G., Hutson, T., Danzi, M. C., Perry, R. B., Santos, C. X. C., Kapustin, A. N., Fleck, R. A., Del Rio, J. A., Carroll, T., Lemmon, V., Bixby, J. L., Shah, A. M., Fainzilber, M. and Di Giovanni, S. (2018) Reactive oxygen species regulate axonal regeneration through the release of exosomal NADPH oxidase 2 complexes into injured axons. Nat Cell Biol. 20, 307-319
Zhao, J., Lee, M. C., Momin, A., Cendan, C. M., Shepherd, S. T., Baker, M. D., Asante, C., Bee, L., Bethry, A., Perkins, J. R., Nassar, M. A., Abrahamsen, B., Dickenson, A., Cobb, B. S., Merkenschlager, M. and Wood, J. N. (2010) Small RNAs control sodium channel expression, nociceptor excitability, and pain thresholds. The Journal of neuroscience : the official journal of the Society for Neuroscience. 30, 10860-10871

Li, X., Gibson, G., Kim, J. S., Kroin, J., Xu, S., van Wijnen, A. J. and Im, H. J. (2011) MicroRNA-146a is linked to pain-related pathophysiology of osteoarthritis. Gene. 480, 34-41

Favereaux, A., Thoumine, O., Bouali-Benazzouz, R., Roques, V., Papon, M. A., Salam, S. A., Drutel, G., Leger, C., Calas, A., Nagy, F. and Landry, M. (2011) Bidirectional integrative regulation of Cav1.2 calcium channel by microRNA miR-103: role in pain. The EMBO journal. 30, 3830-3841

Zhang, Z. J., Guo, J. S., Li, S. S., Wu, X. B., Cao, D. L., Jiang, B. C., Jing, P. B., Bai, X. Q., Li, C. H., Wu, Z. H., Lu, Y. and Gao, Y. J. (2018) TLR8 and its endogenous ligand miR-21 contribute to neuropathic pain in murine DRG. J Exp Med. 215, 3019-3037

Langeslag, M., Malsch, P., Wellina, A. and Kress, M. (2014) Reduced excitability of gp130-deficient nociceptors is associated with increased voltage-gated potassium currents and Kcnq4 channel upregulation. Pflugers Archiv : European journal of physiology. 466, 2153-2165

Namer, B., Orstavik, K., Schmidt, R., Mair, N., Kleggetveit, I. P., Zeidler, M., Martha, T., Jorum, E., Schmelz, M., Kalpa-chidou, T., Kress, M. and Langeslag, M. (2017) Changes in Ionic Conductance Signature of Nociceptive Neurons Underlying Fabry Disease Phenotype. Frontiers in neurology. 8, 335

Cai, L., Liu, X., Guo, Q., Huang, Q., Zhang, Q. and Cao, Z. (2019) MiR-15a attenuates peripheral nerve injury-induced neuropathic pain by targeting AKT3 to regulate autophagy. Genes Genomics

Merighi, A., Salio, C., Ghirri, A., Lossi, L., Ferrini, F., Betelli, C. and Bardon, R. (2008) BDNF as a pain modulator. Prog Neurobiol. 85, 297-317

Thompson, S. W., Bennett, D. L., Kerr, B. J., Bradbury, E. J. and McMahon, S. B. (1999) Brain-derived neurotrophic factor is an endogenous modulator of nociceptive responses in the spinal cord. Proc Natl Acad Sci U S A. 96, 7714-7718

McMahon, S. B. and Priestley, J. V. (1995) Peripheral neuropathies and neurotrophic factors: animal models and clinical perspectives. Curr Opin Neurobiol. 5, 616-624

Geranton, S. M., Morenilla-Palao, C. and Hunt, S. P. (2007) A role for transcriptional repressor methyl-CpG-binding protein 2 and plasticity-related gene serum- and glucocorticoid-inducible kinase 1 in the induction of inflammatory pain states. The Journal of neuroscience : the official journal of the Society for Neuroscience. 27, 6163-6173

Lin, Y. T., Ro, L. S., Wang, H. L. and Chen, J. C. (2011) Up-regulation of dorsal root ganglia BDNF and trkB receptor in inflammatory pain: an in vivo and in vitro study. Journal of neuroinflammation. 8, 126

Crow, M., Khovanov, N., Kelleher, J. H., Sharma, S., Grant, A. D., Bogdanov, Y., Wood, J. N., McMahon, S. B. and Denk, F. (2015) HDAC4 is required for inflammation-associated thermal hypersensitivity. FASEB J. 29, 3370-3378

Bai, G., Wei, D., Zou, S., Ren, K. and Dubner, R. (2010) Inhibition of class II histone deacetylases in the spinal cord attenuates inflammatory hyperalgesia. Molecular pain. 6, 51

Lin, T. B., Hsieh, M. C., Lai, C. Y., Cheng, J. K., Chau, Y. P., Ruan, T., Chen, G. D. and Peng, H. Y. (2015) Modulation of Nerve Injury-induced HDAC4 Cytoplasmic Retention Contributes to Neuropathic Pain in Rats. Anesthesiology. 123, 199-212

Willemsen, H. L., Huo, X. J., Mao-Ying, Q. L., Zijlstra, J., Heijnen, C. J. and Kavelaars, A. (2012) MicroRNA-124 as a novel treatment for persistent hyperalgesia. Journal of neuroinflammation. 9, 143

Yu, W., Zhao, G. Q., Cao, R. J., Zhu, Z. H. and Li, K. (2017) LncRNA NONRATT021972 Was Associated with Neuropathic Pain Scoring in Patients with Type 2 Diabetes. Behav Neurol. 2017, 2941297

Ohayon, D., Vento, S., Sonnier, C., Lafon, P. A., Garces, A., Valmier, J., Rivat, C., Topilko, P., Carroll, P. and Pattyn, A. (2015) Zeb family members and boundary cap cells underlie developmental plasticity of sensory nociceptive neurons. Dev Cell. 33, 343-350

Li, D., Lang, W., Zhou, C., Wu, C., Zhang, F., Liu, Q., Yang, S. and Hao, J. (2018) Upregulation of Microglial ZEB1 Ameliorates Brain Damage after Acute Ischemic Stroke. Cell Rep. 22, 3574-3586

Farley, J. E., Burdett, T. C., Barria, R., Neukomm, L. J., Kenna, K. P., Landers, J. E. and Freeman, M. R. (2018) Transcription factor Pebbled/RREB1 regulates injury-induced axon degeneration. Proc Natl Acad Sci U S A. 115, 1358-1363
neuroscience : the official journal of the Society for Neuroscience. 2019;206:2618-2629.

MicroRNA as repressors of stress

GluA2 receptors via the suppression of microRNA

505

Kunugi, H. (2011) Growth factors stimulate expression of neuronal and glial miR

Cell Biol.

Dopamine

505

Dolan, B. M., Sharp, P. A. and Sheng, M. (2010) Regulation of synaptic structure and function by FMRP

neural plasticity and memory. Neurobiology of learning and memory.

Genome Society.

characterise miRNA function. Mammalian genome : official jo

C. (2008) Using hippocampal microRNA expression differences between mouse inbred strains to

cord injury. J Neurotrauma.

of the spinal cord dorsal horn contributes to reduced GABAergic tone and neuropathic pain after spinal

neuroscience.

Tlx1 are post

Bouchard, M., Luo, P., Chen, C. L., Busslinger, M., Goulding, M., Onimaru, H. and Ma, Q. (2004) Tlx3 and

HU, Y., Abdel Samad, O., Zhang, L., Duan, B., Tong, Q., Lopes, C., Ji, R. R., Lowell, B. B. and Ma, Q.

(2010) VGLUT2-dependent glutamate release from nociceptors is required to sense pain and suppress itch. Neuron. 68, 543-556.

Cheng, L., Arata, A., Mizuguchi, R., Qian, Y., Karunaratne, A., Gray, P. A., Arata, S., Shirasawa, S., Bouchard, M., Luo, P., Chen, C. L., Busslinger, M., Goulding, M., Onimaru, H. and Ma, Q. (2004) Tlx3 and Tlx1 are post-mitotic selector genes determining glutamatergic over GABAergic cell fates. Nature neuroscience. 7, 510-517.

Meisner, J. G., Marsh, A. D. and Marsh, D. R. (2010) Loss of GABAergic interneurons in laminae I-III of the spinal cord dorsal horn contributes to reduced GABAergic tone and neuropathic pain after spinal cord injury. J Neurotrauma. 27, 729-737.

Parsons, M. J., Grimm, C. H., Paya-Cano, J. L., Sugden, K., Nietfeld, W., Lehrach, H. and Schalkwyk, L. C. (2008) Using hippocampal microRNA expression differences between mouse inbred strains to characterise miRNA function. Mammalian genome : official journal of the International Mammalian Genome Society. 19, 552-560.

Bredy, T. W., Lin, Q., Wei, W., Baker-Andresen, D. and Mattick, J. S. (2011) MicroRNA regulation of neural plasticity and memory. Neurobiology of learning and memory. 96, 89-94.

Edbauer, D., Neilson, J. R., Foster, K. A., Wang, C. F., Seeburg, D. P., Batterton, M. N., Tada, T., Dolan, B. M., Sharp, P. A. and Sheng, M. (2010) Regulation of synaptic structure and function by FMRP-associated microRNAs miR-125b and miR-132. Neuron. 65, 373-384.

Saba, R., Storchel, P. H., Aksoy-Aksel, A., Kepura, F., Lippi, G., Plant, T. D. and Schratt, G. M. (2012) Dopamine-regulated microRNA MiR-181a controls GluA2 surface expression in hippocampal neurons. Mol Cell Biol. 32, 619-632.

Numakawa, T., Yamamoto, N., Chiba, S., Richards, M., Ooshima, Y., Kishi, S., Hashido, K., Adachi, N. and Kunugi, H. (2011) Growth factors stimulate expression of neuronal and glial miR-132. Neurosci Lett. 505, 242-247.

Kawashima, H., Numakawa, T., Kumamaru, E., Adachi, N., Mizuno, H., Ninomiya, M., Kunugi, H. and Hashido, K. (2010) Glucocorticoid attenuates brain-derived neurotrophic factor-dependent upregulation of glutamate receptors via the suppression of microRNA-132 expression. Neuroscience. 165, 1301-1311.

Haramati, S., Navon, I., Issler, O., Ezra-Nevo, G., Gil, S., Zwang, R., Hornstein, E. and Chen, A. (2011) MicroRNA as repressors of stress-induced anxiety: the case of amygdalar miR-34. The Journal of Neuroscience : the official journal of the Society for Neuroscience. 31, 14191-14203.
160 Shaltiel, G., Hanan, M., Wolf, Y., Barbash, S., Kovalev, E., Shoham, S. and Soreq, H. (2013) Hippocampal microRNA-132 mediates stress-inducible cognitive deficits through its acetylcholinesterase target. Brain structure & function. 218, 59-72

161 Ni, J., Gao, Y., Gong, S., Guo, S., Hisamitsu, T. and Jiang, X. (2013) Regulation of mu-opioid type 1 receptors by microRNA134 in dorsal root ganglion neurons following peripheral inflammation. European journal of pain (London, England). 17, 313-323

162 Sengupta, J. N., Pochiraju, S., Kannampalli, P., Bruckert, M., Addya, S., Yadav, P., Miranda, A., Shaker, R. and Banerjee, B. (2013) MicroRNA-mediated GABA Alpha1 receptor subunit down-regulation in adult spinal cord following neonatal cystitis-induced chronic visceral pain in rats. Pain. 154, 59-70

163 He, Y., Yang, C., Kirkmire, C. M. and Wang, Z. J. (2010) Regulation of opioid tolerance by let-7 family microRNA targeting the mu opioid receptor. The Journal of neuroscience : the official journal of the Society for Neuroscience. 30, 10251-10258

164 Wu, Q., Hwang, C. K., Zheng, H., Wagley, Y., Lin, H. Y., Kim, D. K., Law, P. Y., Loh, H. H. and Wei, L. N. (2013) MicroRNA 339 down-regulates mu-opioid receptor at the post-transcriptional level in response to opioid treatment. FASEB J. 27, 522-535

165 Fang, S., Zhang, L., Guo, J., Niu, Y., Wu, Y., Li, H., Zhao, L., Li, X., Teng, X., Sun, X., Sun, L., Zhang, M. Q., Chen, R. and Zhao, Y. (2018) NONCODEV5: a comprehensive annotation database for long non-coding RNAs. Nucleic acids research. 46, D308-D314

166 Ma, L., Cao, J., Liu, L., Du, Q., Li, Z., Zou, D., Bajic, V. B. and Zhang, Z. (2019) LnBook: a curated knowledgebase of human long non-coding RNAs. Nucleic acids research. 47, D128-D134

167 Fernandes, J. C. R., Acuña, S. M., Aoki, J. I., Floeter-Winter, L. M. and Muxel, S. M. (2019) Long Non-Coding RNAs in the Regulation of Gene Expression: Physiology and Disease. Noncoding RNA. 5, 17

168 Dahariya, S., Paddibhatla, I., Kumar, S., Raghuwanshi, S., Pallepati, A. and Guti, R. K. (2019) Long non-coding RNA: Classification, biogenesis and functions in blood cells. Molecular immunology. 112, 82-92

169 Quinn, J. J. and Chang, H. Y. (2016) Unique features of long non-coding RNA biogenesis and function. Nature reviews. Genetics. 17, 47-62

170 Yang, J. X., Rastetter, R. H. and Wilhelm, D. (2016) Non-coding RNAs: An Introduction. Advances in experimental medicine and biology. 886, 13-32

171 Jarroux, J., Morillon, A. and Pinskaya, M. (2017) History, Discovery, and Classification of IncRNAs. Advances in experimental medicine and biology. 1008, 1-46

172 Carlevaro-Fita, J. and Johnson, R. (2019) Global Positioning System: Understanding Long Noncoding RNAs through Subcellular Localization. Molecular cell. 73, 869-883

173 Schmitz, S. U., Grote, P. and Herrmann, B. G. (2016) Mechanisms of long noncoding RNA function in development and disease. Cellular and Molecular Life Sciences. 73, 2491-2509

174 Luo, L., Ji, L. D., Cai, J. J., Feng, M., Zhou, M., Hu, S. P., Xu, J. and Zhou, W. H. (2018) Microarray Analysis of Long Noncoding RNAs in Female Diabetic Peripheral Neuropathy Patients. Cell Physiol Biochem. 46, 1209-1217

175 Suwal, A., Hao, J. L., Liu, X. F., Zhou, D. D., Pant, O. P., Gao, Y., Hui, P., Dai, X. X. and Lu, C. W. (2019) NONRATT021972 long-noncoding RNA: A promising IncRNA in diabetes-related diseases. International journal of medical sciences. 16, 902-908

176 Wang, L., Luo, T., Bao, Z., Li, Y. and Bu, W. (2018) Intrathecal circHIPK3 shRNA alleviates neuropathic pain in diabetic rats. Biochim Biophys Res Commun. 505, 644-650

177 Peng, H., Zou, L., Xie, J., Wu, H., Wu, B., Zhu, G., Lv, Q., Zhang, X., Liu, S., Li, G., Xu, H., Gao, Y., Yu, X., Cang, C., Wang, S., Xue, Y. and Liang, S. (2017) IncRNA NONRATT021972 siRNA Decreases Diabetic Neuropathy Pain Mediated by the P2X3 Receptor in Dorsal Root Ganglia. Mol Neurobiol. 54, 511-523

178 Wang, S., Xu, H., Zou, L., Xie, J., Wu, H., Wu, B., Yi, Z., Lv, Q., Zhang, X., Ying, M., Liu, S., Li, G., Gao, Y., Xu, C., Zang, C., Xue, Y. and Liang, S. (2016) LncRNA uc.48+ is involved in diabetic neuropathic pain mediated by the P2X3 receptor in the dorsal root ganglia. Purinergic Signal. 12, 139-148

179 Wu, B., Zhang, C., Zou, L., Ma, Y., Huang, K., Lv, Q., Zhang, X., Wang, S., Xue, Y., Yi, Z., Jia, T., Zhao, S., Liu, S., Xu, H., Li, G. and Liang, S. (2016) LncRNA uc.48+ siRNA improved diabetic sympathetic neuropathy in type 2 diabetic rats mediated by P2X7 receptor in SCG. Autonomic neuroscience : basic & clinical. 197, 14-18

180 Yu, B., Zhou, S., Hu, W., Qian, T., Gao, R., Ding, G., Ding, F. and Gu, X. (2013) Altered long noncoding RNA expressions in dorsal root ganglion after rat sciatic nerve injury. Neurosci Lett. 534, 117-122
Neuronal Signaling. This is an Accepted Manuscript. You are encouraged to use the Version of Record that, when published, will replace this version. The most up-to-date version is available at https://doi.org/10.1042/NS20190099

102 contributions to neuropathic pain by silencing Kcna2 in primary afferent neurons. Nature neuroscience.

103 Tiwari, V., Gao, Y. J., Hoffman, P. N., Mogil, J. S., Oreno, C. and Bennett, D. L. (2019) Comprehensive analysis of long noncoding RNA expression in dorsal root ganglion reveals cell-type specificity and dysregulation after nerve injury. Pain. 160, 463-485

104 Zhou, J., Fan, Y. and Chen, H. (2017) Analyses of long non-coding RNA and mRNA profiles in the spinal cord of rats using RNA sequencing during the progression of neuropathic pain in an SNI model. RNA Biol. 14, 1810-1826

105 Jiang, B. C., Sun, W. X., He, L. N., Cao, D. L., Zhang, Z. J. and Gao, Y. J. (2015) Identification of IncRNA expression profile in the spinal cord of mice following spinal nerve ligation-induced neuropathic pain. Molecular pain. 11, 43

106 Pan, B., Zhou, H. X., Liu, Y., Yan, J. Y., Wang, Y., Yao, X., Deng, Y. Q., Chen, S. Y., Lu, L., Wei, Z. J., Kong, X. H. and Feng, S. Q. (2017) Time-dependent differential expression of long non-coding RNAs following peripheral nerve injury. International journal of molecular medicine. 39, 1381-1392

107 Raju, H. B., Englander, Z., Capobianco, E., Tsinoremas, N. F. and Lerch, J. K. (2014) Identification of potential therapeutic targets in a model of neuropathic pain. Frontiers in genetics. 5, 131

108 Wang, W.-T., Sun, Y.-M., Huang, W., He, B., Zhao, Y.-N. and Chen, Y.-Q. (2016) Genome-wide Long Non-coding RNA Analysis Identified Circulating LncRNAs as Novel Non-invasive Diagnostic Biomarkers for Gynecological Disease. Scientific reports. 6, 23343

109 Li, Y., Li, Q., Wang, C., Li, S. and Yu, L. (2019) Long Noncoding RNA Expression Profile in BV2 Microglial Cells Exposed to Lipopolysaccharide. BioMed research international. 2019, 5387407

110 Xu, S., Ao, J., Gu, H., Wang, X., Xie, C., Meng, D., Wang, L. and Liu, M. (2017) IL-22 Impedes the Proliferation of Schwann cells: Transcriptome Sequencing and Bioinformatics Analysis. Mol Neurobiol. 54, 2395-2405

111 Iwasaki, H., Sakai, A., Maruyama, M., Ito, T., Sakamoto, A. and Suzuki, H. (2019) Increased H19 Long Non-coding RNA Expression in Schwann Cells in Peripheral Neuropathic Pain. J Nippon Med Sch. 86, 215-221

112 Liu, C. L., Deng, Z. Y., Du, E. R. and Xu, C. S. (2018) Long noncoding RNA BC168687 small interfering RNA reduces high glucose and high free fatty acidinduced expression of P2X7 receptors in satellite glial cells. Molecular medicine reports. 17, 5851-5859

113 Liu, C., Li, C., Deng, Z., Du, E. and Xu, C. (2018) Long Non-coding RNA BC168687 is Involved in TRPV1-mediated Diabetic Neuropathic Pain in Rats. Neuroscience. 374, 214-222

114 Liu, C., Tao, J., Wu, H., Yang, Y., Chen, Q., Deng, Z., Liu, J. and Xu, C. (2017) Effects of LncRNA BC168687 siRNA on Diabetic Neuropathic Pain Mediated by P2X7 Receptor on SGCS in DRG of Rats. BioMed research international. 2017, 7831251

115 Li, G., Jiang, H., Zheng, C., Zhu, G., Xu, Y., Sheng, X., Wu, B., Guo, J., Zhu, S., Zhan, Y., Lin, W., Ding, R., Zhang, C., Liu, S., Zou, L., Yi, Z. and Liang, S. (2017) Long noncoding RNA MRAK009713 is a novel regulator of neuropathic pain in rats. Pain. 158, 2042-2052

116 Liu, S., Zou, L., Xie, J., Xie, W., Wen, S., Xie, Q., Gao, Y., Li, G., Zhang, C., Xu, C., Xu, H., Wu, B., Lv, Q., Zhang, X., Wang, S., Xue, Y. and Liang, S. (2016) LncRNA NONRATT021972 siRNA regulates neuropathic pain behaviors in type 2 diabetic rats through the P2X7 receptor in dorsal root ganglia. Mol Brain. 9, 44

117 Hu, J. Z., Rong, Z. J., Li, M., Li, P., Jiang, L. Y., Luo, Z. X., Duan, C. Y., Cao, Y. and Lu, H. B. (2019) Silencing of IncRNA PKIA-AS1 Attenuates Spinal Nerve Ligation-Induced Neuropathic Pain Through Epigenetic Downregulation of CD66 Expression. Frontiers in cellular neuroscience. 13, 50

118 Xiong, W., Tan, M., Tong, Z., Yin, C., He, L., Liu, L., Shen, Y., Guan, S., Ge, H., Li, G., Liang, S. and Gao, Y. (2019) Effects of long non-coding RNA uc.48+ on pain transmission in trigeminal neuralgia. Brain Res Bull. 147, 92-100

119 Zhao, X., Tang, Z., Zhang, H., Atianjoh, F. E., Zhao, J. Y., Liang, L., Wang, W., Guan, X., Kao, S. C., Tiwari, V., Gao, Y. J., Hoffman, P. N., Cui, H., Li, M., Dong, X. and Tao, Y. X. (2013) A long noncoding RNA contributes to neuropathic pain by silencing KcnA2 in primary afferent neurons. Nature neuroscience. 16, 1024-1031
Martinez-Moreno, M., O'Shea, T. M., Zepecki, J. P., Olaru, A., Ness, J. K., Langer, R. and Tapinos, N. (2017) Regulation of Peripheral Myelination through Transcriptional Buffering of Egr2 by an Antisense Long Non-coding RNA. Cell Rep. 20, 1950-1963

Wu, S., Marie Lutz, B., Miao, X., Liang, L., Mo, K., Chang, Y. J., Du, P., Soteropoulos, P., Tian, B., Kaufman, A. G., Bekker, A., Hu, Y. and Tao, Y. X. (2016) Dorsal root ganglion transcriptome analysis following peripheral nerve injury in mice. Molecular pain. 12

Guo, G., Ren, S., Kang, Y., Liu, Y., Duscher, D., Machens, H. G. and Chen, Z. (2019) Microarray analyses of IncRNAs and mRNAs expression profiling associated with diabetic peripheral neuropathy in rats. J Cell Biochem. 120, 15347-15359

Zhao, X., Tang, Z., Zhang, H., Atianjoh, F. E., Zhao, J.-Y., Liang, L., Wang, W., Guan, X., Kao, S.-C., Tiwari, V., Gao, Y.-J., Hoffmann, P. N., Cui, H., Li, M., Dong, X. and Tao, Y.-X. (2013) A long noncoding RNA contributes to neuropathic pain by silencing Kcna2 in primary afferent neurons. Nature neuroscience. 16, 1024

Xiong, W., Tan, M., Tong, Z., Yin, C., He, L., Liu, L., Shen, Y., Guan, S., Ge, H., Li, G., Liang, S. and Gao, Y. (2019) Effects of long non-coding RNA uc.48+ on pain transmission in trigeminal neuralgia. Brain Research Bulletin. 147, 92-100

Yao, C., Wang, J., Zhang, H., Zhou, S., Qian, T., Ding, F., Gu, X. and Yu, B. (2015) Long non-coding RNA uc.217 regulates neurite outgrowth in dorsal root ganglion neurons following peripheral nerve injury. Eur J Neurosci. 42, 1718-1725

LncRNA expression in the spinal cord modulated by minocycline in a mouse model of spared nerve injury. Journal of pain research. 10, 2503-2514

Zhou, J., Xiong, Q., Chen, H., Yang, C. and Fan, Y. (2017) Identification of the Spinal Expression Profile of Non-coding RNAs Involved in Neuropathic Pain Following Spared Nerve Injury by Sequence Analysis. Frontiers in molecular neuroscience. 10, 91

Cao, S., Deng, W., Li, Y., Qin, B., Zhang, L., Yu, S., Xie, P., Xiao, Z. and Yu, T. (2017) Chronic constriction injury of sciatic nerve changes circular RNA expression in rat spinal dorsal horn. Journal of pain research. 10, 1687-1696

Du, H., Liu, Z., Tan, X., Ma, Y. and Gong, Q. (2019) Identification of the Genome-wide Expression Patterns of Long Non-coding RNAs and mRNAs in Mice with Streptozotocin-induced Diabetic Neuropathic Pain. Neuroscience. 402, 90-103
